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Abstract 
 Lung cancer is a high-incidence disease with low survival despite surgical advances 
and concurrent chemo-radiotherapy strategies.  Image-guided radiotherapy provides for 
treatment measures, however, significant challenges exist for imaging, treatment planning, 
and delivery of radiation due to the influence of respiratory motion.  4D-CT imaging is 
capable of improving image quality of thoracic target volumes influenced by respiratory 
motion. 4D-CT-based treatment planning strategies requires highly accurate anatomical 
segmentation of tumour volumes for radiotherapy treatment plan optimization.  Variable 
segmentation of tumour volumes significantly contributes to uncertainty in radiotherapy 
planning due to a lack of knowledge regarding the exact shape of the lesion and difficulty in 
quantifying variability.  As image-segmentation is one of the earliest tasks in the 
radiotherapy process, inherent geometric uncertainties affect subsequent stages, potentially 
jeopardizing patient outcomes.  Thus, this work assesses and suggests strategies for 
mitigation of segmentation-related geometric uncertainties in 4D-CT-based lung cancer 
radiotherapy at pre- and post-treatment planning stages.  
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Chapter 1  
1 Introduction 
1.1 Lung cancer 
 Lung cancer is the second most diagnosed cancer in Canada with an estimated 
25,600 incident cases.  Additionally, it is the leading cause of cancer death amongst both 
men and women with an estimated 20,100 deaths, a total that is greater than the next 
three most prevalent cancers combined [1].  The Canadian Cancer Society has stopped 
reporting on the 5-year survival rates for all cancers in Canada, however, as of 2011, the 
5-year relative survival ratio for lung cancer is quite low at 16% [2].  Cancer of the lung 
is divided into two major subclasses and, after diagnosis, 4 major stages of disease based 
on the TNM system.  The two major subclasses consist of small cell lung cancer (SCLC) 
and non-small small cell lung cancer (NSCLC).  In the case of NSCLC, which accounts 
for roughly 85% of all lung cancer [3] [4] the TNM staging system is used to further 
classify the tumour on a patient specific level.  TNM staging denotes tumour, node, and 
metastasis (Table 1-1).  Increasing TNM stage is generally reflected by disease 
progression, where both the tumour size and the spread of the disease increases while the 
5-year survival correspondingly decrease.  Typically, SCLC is more aggressive than 
NSCLC and is classified by two stages, limited (30% of patients) and extensive (70% of 
patients).  Limited-stage classifies patients who present with disease confined to one 
hemithorax, with or without mediastinal, contralateral hilar, or supraclavicular or scalene 
lymph nodes.  Advanced-stage classifies patients presenting with disease involvement at 
any other location that cannot be covered by a tolerable radiotherapy field [5] [6].  
 
 
 
2 
 
Table 1-1: NSCLC TNM staging classifications.  Table adapted from [5]. 
Stage TNM 5-Year Survival 
IA T1N0M0 75% 
IB T2N0M0 55% 
IIA T1N1M0 40% 
IIB T2N1M0 or T3N0M0 40% 
IIIA T1-2N2M0 or T3N1-2M0 10-35% 
IIIB T4NxM0 or TxN3M0 5% 
IV TxNxM1 <5% 
*Where x denotes any possible staging value 
 
 
T denotes tumour size 
1: Tumours less than 3cm in greatest direction, surrounded by lung and without 
invasion into main bronchus 
2: Tumour without any of: more than 3cm in any direction; invasion into main 
bronchus, more than 2cm from carina; or obstructive pneumonitis, but not involving 
the entire lung 
3: Tumour with any of: invasion into chest wall, diaphragm, mediastinal pleura or 
parietal pericardium; invasion into the main bronchus within 2cm of carina, but not 
invading it; or obstructive pneumonitis of the entire lung 
4: Tumour with any of: invasion into mediastinum, heart, large vessels, trachea, 
esophagus, vertebra, or carina; separate tumour nodules in the same lobe; or 
malignant pleural effusion 
N denotes extent of regional Lymph Node spread 
0: No spread 
1-3: Increasing spread to nodes 
M denotes distant Metastases 
0: No metastatic disease 
1: Distant metastases found (including pleural or pericardial effusion) 
 
1.2 Treatment Strategies 
1.2.1 Surgery 
 For patients diagnosed with NSCLC, surgery is considered to be the most 
successful treatment option [7].  However, for this to be a viable option, the cancer must 
be contained (stages I-IIIA) with preference given to earliest stages.   Currently, ongoing 
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efforts are being made to expand eligibility [8].  Resectability and possible complications 
are based on preoperative staging of the disease, but issues of operability are based on 
patient evaluation and review of surgical approaches.  The standard for surgical 
intervention is lobectomy for resectable tumours in patients able to tolerate such surgery 
[5] [7] [9].  This standard is based on findings in prospective randomized controlled trials 
showing strong evidence for increased long-term survival with decreased risk of local 
recurrence for patients undergoing lobectomy [10].  For patients with SCLC, surgery is 
again only an option for early stage, non-node positive, non-metastatic patients.  
However, very few patients present with limited extent disease or early stage SCLC and, 
therefore, surgical intervention is only a consideration for a limited number of patients [5] 
[6] [11].  The number of patients presenting with NSCLC eligible for surgical resection 
remains low at roughly 10% while those presenting with SCLC eligible for surgery is 
<1%.  Those with NSCLC who present with stage IA and IIIA and receive surgical 
resection with a chemotherapeutic follow-up tend to experience a 75% and 10% 5-year 
survival rate, respectively while SCLC patients undergoing surgical resection with 
chemotherapy experience a 5-year survival of approximately 50% [5]. 
1.2.2 Chemotherapy 
 Chemotherapy is the treatment of cancer through the use of intravenous cytotoxic 
agents administered with neo-adjuvant/adjuvant (curative) or palliative intent.  The 
intravenous nature of delivery is done to allow the chemotherapeutic agents to act 
systemically through the body in hopes of killing cancerous cells.  Chemotherapy is 
commonly used in conjunction with surgical intervention and radiation therapy.  Neo-
adjuvant treatments are used prior to surgery in efforts to downgrade the tumour in hopes 
of slowing and/or reversing its growth in efforts to make surgical intervention possible 
[5].  For patients presenting with M0 disease, adjuvant treatment regimens are 
implemented after concurrent radiotherapy treatments for curative intent.  Studies 
implementing phase 3 randomized trials have shown strong support in the use of 
chemotherapy after resection of stage IB, II, IIA, and IIIA, however, further work is 
needed in determining its usefulness in the treatment of patients with stage IA resected 
cancers [7] [12] [13] [14].  For NSCLC, approximately 70% of patients present with 
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locally advanced and/or metastatic disease thereby necessitating palliative 
chemotherapeutic treatment regimens [7] [15].  Again, Phase III trials have shown the 
superiority of systemic chemotherapy over best supportive care in locally advanced stage 
and/or metastatic NSCLC patients.  In SCLC, the possibility of resection is quite low as 
this disease is usually diagnosed at a locally advanced stage.  Concurrent chemotherapy 
and radiotherapy are routinely used for limited stage patients and palliative chemotherapy 
is a frequently used for advanced stage patients [6] [16].  Studies looking at 
chemotherapeutic agents in different combination and doses have shown fairly consistent 
response when ≥2 drugs are given over ≥4 treatment cycles [16].  Roughly 60% of 
patients with extensive disease and 80% of patients with limited disease will respond to 
treatment [5].   
1.2.3 Targeted Therapy 
 In NSCLC, targeted therapy strategies have received greater attention in recent 
years.  Generally speaking, targeted therapies attempt to take advantage of the fact that 
most lung cancer tumour cells cause alterations in major cell-signaling and regulatory 
pathways.  These alterations include, but are not limited to, alterations in receptor 
tyrosine kinases such as epidermal growth factor receptors (EGFR), vascular endothelial 
growth factor-induced processes (VEGF), angiogenesis pathways, apoptosis, cell cycle 
control and many others [7].  Targeted therapies including EGFR, inhibitors, antisense 
molecules and immune modulators have yielded negative results leading to the notion 
that while of great interest, targeted therapies are still quite variable in their effectiveness 
and as such, require further research and additional clinical trials in hopes of widespread 
acceptance  [7] [17]. 
1.2.4 Radiotherapy 
 Radiation therapy (or radiotherapy) (RT) refers to the use of high-energy X-ray 
radiation targeted through image-guidance to preferentially kill tumour and cancerous 
nodal cells within a patient's body.  The high-energy radiation beams travel through the 
patient's body and deposit dose, which is measured in energy per unit mass in units Gray 
(Gy), along the track.  Radiation therapy generally ranges from static beams to multiple 
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rotating beams all exploiting the concept of superposition to deposit large doses in 
tumour volume while sparing surrounding normal tissue within the human body, as seen 
in Figure 1-1.   
 
Figure 1-1: Principle of superposition utilized as multiple radiation beams converge on a 
single target in radiotherapy.  Isodose lines are corresponding to doses in top left-hand 
corner are indicated at the center of beams’ intersection.  The target volume is indicated 
as the black contour. 
 
 The primary goal of radiotherapy is to maximize tumour control probability and 
local control while minimizing normal tissue complication probability. Therefore the 
mitigation of high dose to organs at risk (OARs) and healthy tissue is crucial to the 
success of radiotherapy and avoiding negative radiation-related side effects.  The multi-
step processes that go into a successful radiotherapy treatment plan are seen in Figure 1-
2.   
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Figure 1-2: Stages of the radiotherapy process.  Tumour volume, target volume and 
critical structure segmentation occurs during the localization processes.  The inherent 
uncertainty can then propagate down the treatment chain from [18] with permission of 
IOP Publishing Limited, Bristol UK] 
 
 For radiotherapy planning, a total dose is prescribed, typically broken down into 
multiple treatment sessions or treatment fractions.  Modern radiotherapy employs the use 
of 3- and 4-dimensional computed tomography imaging of the patient's body to target the 
tumour volume and guide the high-energy X-ray beams.  Within the CT dataset, 
physician segments the gross tumour volume (GTV), based on his or her own clinical 
experiences as well as disease specific characteristics such as pattern specific progression 
and staging.  Two additional margins are added on top of the GTV to account for 
different types of uncertainty in radiation delivery.  The first supplementary margin is 
added to create the clinical target volume (CTV), which accounts for uncertainty related 
to microscopic spread of disease that is not visible to the physician in the CT dataset.  A 
second margin is subsequently added on top of the CTV called the planning target 
volume (PTV), which accounts for geometric uncertainty that arises in patient setup and 
movement during treatment. Subsequently, OARs and critical structures are also 
segmented.  OAR segmentations are necessary as they serve as dose limiting structures 
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during treatment plan optimization and need to be spared from high radiation doses for 
successful treatment with minimal toxicities and to ensure suitable long-term quality of 
life for patients.  Finally, the isocentre, defined as the anatomical point where all 
treatment beams intersect within the image dataset, is chosen such that a constant 
reference point can be maintained within the patient specific dataset throughout 
treatment. On the linear accelerator, the isocentre represents the intersection of all axes of 
rotations, including the gantry, collimator, and couch. This allows therapists to have a 
general point of reference during each treatment session to aid in treatment setup [18] 
[19].  Finally, the treatment planning system (TPS) is used for radiotherapy treatment 
planning, optimization and 3-dimensional dose calculation. 
 The Radiation Therapy Oncology Group (RTOG) currently works to establish 
clinical standards of treatment for radiotherapy in North America through clinical 
research-based treatment protocol initiatives.  In particular, the RTOG 88-08 Phase III 
clinical trial aimed to determine the optimal dose prescription and fractionation scheme.  
This study compared 40 Gy in 20 daily fractions, a 40 Gy in 20 fractions split course arm, 
50 Gy in 25 daily fractions, and 60 Gy in 30 daily fractions.  Local failure rates were 
48%, 38%, and 27%, respectively [20].  While these survival rates didn't demonstrate 
statistically significant differences, 60 Gy in 30 daily fractions was established as the 
clinical standard for treating advanced stage lung cancer with radiotherapy.  The median 
survival for patients receiving radiation treatment of 60-66 Gy is 17 months with a 4-year 
survival of 21% [21].  In addition to determining the clinical standard for radiotherapy 
alone, both RTOG and other independent investigators have worked to establish both the 
importance of and a clinical standard for radiotherapy with concurrent chemotherapy.  
Phase III trials have demonstrated that concurrent treatment strategies improve upon 5-
year survival rates compared to radiotherapy on its own [7] [22] [23] while RTOG 9410 
demonstrated improved survival for concurrent chemo-radiation treatment strategies as 
opposed to sequential treatment [24].  While advanced stage NSCLC patients are 
typically prescribed radiation doses in 2 Gy fractions for conventional radiotherapy, 
recent work has shown an improvement in local control and survival rates for increased 
per fraction doses in early stage (~T1/T2, M0, N0) NSCLC patients.  This treatment 
strategy is referred to as Stereotactic Body Radiation Therapy (SBRT).  SBRT involves 
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highly precise, high dose radiation to the GTV alone, usually over the course of 1-5 days 
as opposed to weeks for standard lung cancer radiotherapy.   For SCLC patients, 
randomized controlled trials have shown local control at the primary tumour site with a 
smaller number of relapses however, survival was not increased due to a high percentage 
of patients presenting with extensive disease and death occurring due to spread of 
metastatic disease combined with chemotherapeutic failure.  Concurrent chemo-radiation 
treatments showed a small increase in survival (~4%) and have subsequently been 
established as the clinical standard for patients who show increased response to 
chemotherapy [6] [25] [26] [27] [28] [29]. 
 
1.3 Dosimetry and Radiobiology of Radiotherapy 
1.3.1 Dosimetric and Dose-volume Analysis in Radiotherapy 
 As radiotherapy is guided by 3- or 4-dimensional imaging, radiation dose 
calculations must be made in the image space by the treatment planning system (TPS) to 
create an optimal 3-dimensional dose distribution based on the target volume and normal 
tissue segmentations.  To quantitatively evaluate these 3-dimensional dose distributions, 
dose-volume histograms (DVH) are one way to graphically summarize the radiotherapy 
dose distribution of target volumes and OAR's.   
 Two types of DVH's are currently used for radiotherapy plan evaluation and 
approval in the clinical setting.  Differential DVH is a histogram that is plotted as the 
accumulated volume of elements, or voxel, which is typically defined by the dose grid 
size used in treatment planning, for a given structure that receives dose in a specified 
dose interval against a set of equidistant dose intervals or dose bins.  The cumulative 
DVH is a plot of the volume receiving a dose greater than or equal to a given dose against 
that dose across the expected dose range.  This is typically calculated by integrating the 
information provided by a differential DVH. The end product appears as the volume 
specified by the percentage of a given structure's total volume receiving a given dose or 
more [30].   
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Figure 1-3: Examples of corresponding differential (a) and cumulative (b) DVHs for an 
individual patient.  
 
The DVH allows for dosimetric evaluation of treatment plans, including the dose 
(Gy) received by X% of a particular structure's volume (D[volume]), and/or the relative 
volume (%) receiving X dose (V[dose]).  The DVH also allows for the analysis of the 
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dose distribution in terms of dose homogeneity/heterogeneity throughout the target 
volume and the presence of hot and cold spots.   
For lung cancer radiotherapy, the most common biological endpoints for 
dosimetric analysis constituting radiation-induced lung injury (RILI) are radiation 
pneumonitis (RP) and radiation induced lung fibrosis.  The dosimetric parameters most 
commonly used to predict these side effects consist of the mean lung dose (MLD) which 
is defined as the average dose in the total lung minus the GTV and the relative volume of 
the lungs receiving at least the specified dose in Gy (V[dose]) [31].  Madani et al. 
performed a review of multiple studies on the correlation between dosimetric parameters 
describing lung dose-volume parameters that determine the radiation-dose volume effects 
in the lung based on information based on the dose-volume histogram and incidence of 
radiation related side effects [31].  A summary of their analysis can be seen in Table 1-2 
[31] [32] [33] [34] [35] [36] [37] [38] [39] [40]. 
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Table 1-2: Indices related to physical dose characteristics, or dosimetric parameters of 
radiotherapy as derived from post-treatment planning optimization DVH.  Adapted from 
Madani et al. [31] 
Dosimetric parameter  RILI     
Type Value  Incidence
a 
(%) 
Score Endpoint
b
 Patient No. 
(Total) 
Reference 
MLD
c
 (GY) ≤15, 17.5-20, 22.5-
25, ≥27.5 
 0, 13, 21, 
43 
RTOG RP (all) 66(15) Oetzel et al., 
1995
34
 
 0-8, 8-16, 16-24, 24-
36 
 5, 11, 18, 
43 
SWOG RP (≥2) 540 Kwa et al., 1998
35
 
 <20, >20  8, 24 RTOG RP (≥2) 99(42)  Graham et al., 
1999
36
 
 <10, 10-20, 21-30, 
>30 
 10, 16, 
27, 44 
CTC 
v.2.0 
RP (all) 201(121) Hernando et al., 
2001
37
 
V10(%) >33  53 LENT-
SOMA 
RP (≥1) 96(63) Claude et al., 
2004
38
 
V20(%) <22, 22-31, 31-40  0, 7, 13 RTOG RP (≥2) 99(42) Graham et al., 
1999
36
 
 ≤25, ≥26, ≥32  14, 63, 32 CTC 
v.2.0 
RP (2) 71(71) Tsujino et al., 
2003
39
 
 >18  56   96(63) Claude et al., 
2004
38
 
V25(%) ≤30, >30  4, 38 RTOG RP (≥3) 31 Armstrong et al., 
1995
40
 
V30(%) ≤18, >18  6, 24 CTC 
v.2.0 
RP (all) 201(121) Hernando et al., 
2001
37
 
 >13  56   96(63) Claude et al., 
2004
38
 
V40(%) >10  56   96(63) Claude et al., 
2004
38
 
V50(%) >5  53   96(63) Claude et al., 
2004
38
 
Lyman 
NTCP
c
 
1st, 2nd, 3rd, 4th 
quartiles 
 0, 5, 14, 
29 
SWOG RP (≥1) 42 Martel et al., 
1994
41
 
 1st, 2nd, 3rd, 4th 
quartiles 
 10, 18, 
16, 33
d
 
CTC 
v.2.0 
RP (all) 201(121) Hernando et al., 
2001
37
 
Kutcher 
NTCP(%) 
<12, ≥12  0, 29 RTOG RP (≥3) 31 Armstrong et al., 
1995
40
 
 1st, 2nd, 3rd, 4th 
quartiles 
 29, 12, 
29, 38 
In-
house 
RILI 100(30) Marks et al., 
1997
33
 
NTCP(%) <30, ≥30  10, 29 RTOG RP (all) 66(15) Oetzel et al., 
1995
34
 
CT: chemotherapy; CTC: common toxicity criteria; MLD: mean lung dose; NTCP: normal tissue complication 
probability; RILI: radiation-induced lung injury comprising RP and pulmonary fibrosis; RP: radiation pneumonitis; RT: 
radiation therapy; RTOG: Radiation Therapy Oncology Group; SCLC: small cell lung cancer; SWOG: Southwest 
Oncology Group; V10, V20, V25, V30, V40 and V50: the relative volume (in %) of the lungs receiving at least 10, 20, 
25, 30, 40, and 50 Gy, respectively.  
a
Incidence of RILI, 
b
Grades are in parenthesis, 
c
Lungs analyzed as separate organ, 
d
Average observed probabilities 
 
 Madani et al. showed differences in MLD, V20, and V30 in patients with and 
without RP suggesting the use of these parameters being used as treatment planning 
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objective endpoints in thoracic radiotherapy.  However, they also concede that radiation 
pneumonitis can occur at lower doses as well.  Additionally, a systematic review 
performed by Rodrigues et al. [41] demonstrated that while it is clear that DVH 
parameters are associated with RP risk, the predictive power of these measures is 
somewhat lacking and suffers from a high level of false negative rates.  MLD was shown 
to be of somewhat variable predictive power, with accuracy influenced by factors 
including tumour location, accuracy of dose calculation algorithms and combination with 
chemotherapy [42].  Dosimetric parameters that are indicative of radiation induced lung 
fibrosis have also been subject to a great deal of uncertainty.  Oh et al. [43] argued that its 
importance was equal to that of radiation pneumontis, and it's influence on the long-term 
health of lung cancer survivors was even greater than that of RP and other RILI.  Their 
results are also summarized in Table 1-2.  Their work showed that the volume of fibrosis 
in lung cancer patients continuously increased with the V[dose] parameter as reference 
dose increased.  As such, no threshold dose for fibrosis was found in the conventional 
prescription dose range.  Most recently, Marks et al. [42] summarized the radiation dose-
volume effects in the lung and stated that the recommendation of dose/volume limits is a 
challenge due to the lack of clear and/or consistent dose thresholds and the variability of 
what is considered "acceptable" risk for patients varies from patient to patient depending 
on the clinical scenario.  They concluded that the correlations between dosimetric 
parameters and RILI endpoints, RP, fibrosis, and dyspnea were inconsistent and as such, 
can only be defined based on the technique used to treat the patient.   
1.3.2 Radiobiological Models in Radiotherapy 
 Radiobiology is the study of radiation and its effects on biological systems and 
physiological processes.  Chemical alterations of deoxyribonucleic acid (DNA) occur 
within cells due to either direct or indirect action of high-energy photons (~ >1 KeV).   
Direct action occurs when x-ray photon absorption creates a secondary electron that that 
interacts directly with the DNA to cause a double strand break (DSB).  A DSB is also 
likely to be accompanied by extensive base damage, and as such, means that the DSB 
most significantly correlates with chromosomal aberrations and subsequent cell death.  
Indirect action occurs when the secondary electron interacts with other molecules in the 
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cell, most commonly water, to produce free radicals capable of diffusing far enough to 
cause DNA single strand breaks (SSB) [44].   
 Mammalian survival curves are expressed mathematically by way of a second -
order polynomial termed the linear-quadratic (LQ) model.  The formula for this model is 
given by the following expression: 
   (1) 
In the case of chromosomal aberrations, effects differ at high and low doses.  At low 
doses, the same electron may cause both breaks and the probability of an exchange 
aberration is proportional to dose (D). At higher doses, the two breaks are more likely to 
be caused by separate electrons. The probability of an exchange aberration is proportional 
to the square of the dose (D2).  This effect is similarly reflected in overall cellular 
survival.  For densely ionizing radiations, the dose-response curve is a straight line from 
the origin showing survival as an exponential function of dose that is described by just 
one parameter, the slope. For sparsely ionizing radiations, such as x-rays and γ-rays, the 
dose-response curve has an initial linear slope, followed by a shoulder.  At higher doses, 
the curve becomes straight again.  There are two components of cell killing.  The first is 
the low dose, linear portion of the survival curve which is proportional to dose (αD) and 
the second is the curved portion, proportional to the square of the dose (βD2). The dose at 
which the linear and quadratic components are equal is the ratio α/β. This parameter (α/β) 
can be used to describe the shape of any survival curve [44].  This is because the 
parameter is not the same for all mammalian tissues.  Generally, this parameter ranges 
from 7 to 20 Gy for early-responding tissues and 0.5 to 6 Gy for late-responding tissues 
[45].  The relevance of this measure is that late-responding tissues are more sensitive 
dose fractionation than early-responding tissues.  This means that as dose fractionation is 
reduced, late-responding tissues are better spared.  Typical normal, healthy tissues has an 
α/β ~ 3 while tumour cells have an α/β ~ 10.  Therefore, if dose-limiting structures and 
normal cells are late responding, there is a better ability to spare them while giving 
considerably higher doses to the tumour cells subject to early response through dose 
fractionation.  Accurate knowledge of the α/β relationship is therefore needed to both 
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ensure successful and accurate radiotherapy, and in quantitative evaluations of plan 
effectiveness via tumour control probability and normal tissue complication probability. 
1.3.2.1 TCP and NTCP 
 The commonly accepted goal of radiotherapy is to maximize the tumour control 
probability (TCP) while mitigating the normal tissue complication probability (NTCP).  
The ability to predict both these probabilities is of great interest as it provides additional 
information pertaining to treatment plan evaluation and comparison.  While many models 
exist for estimating these probabilities, few if any have garnered acceptance in the 
clinical setting.  This is mainly due to the fact that most models utilize assumptions that 
are extremely difficult to verify in-vivo.  As such, the use of radiobiological indices are 
meant to compliment the dose-volume indices discussed previously in evaluating 
competing treatment plans, differing prescription doses, differing treatment strategies and 
overall plan efficacy. The TCP model used in chapter 2 is based on Poisson statistics and 
follows the assumptions that tumour clonogens are uniformly distributed throughout the 
tumour volume, all clonogens are equally sensitive to radiation, and that the dose 
delivered is high enough that clonogen survival is a rare event [46] [47].  Ergo, if all 
clonogens within the tumour are killed, the tumour is controlled.  For all treatment plan 
evaluation, normalized total dose corrections were not needed as all patient plans were 
based on 2 Gy fractionations.  For TCP calculations, a D50 of 70 Gy, a γ of 2.0 were 
assumed and an 	
 = 10.  TCP calculations for this study are further explained in 
chapter 2 and did not take into account dose inhomogeneities within the target sub-
volume.  Parameters for TCP calculations were chosen in accordance with the study 
performed by van Baardwijk et al. [48].  The NTCP was also analyzed in chapter 2 using 
the Lyman-Kutcher-Burman (LKB) model [49] [50] [51] with parameters chosen in 
accordance with the study done Tucker et al. [52].  Their work demonstrated an 
improvement in the predictive power of the LKB NTCP model using the effective dose 
parameter as opposed to the MLD as the dosimetric parameter of interest in determining 
RILI risk.  Thus, for LKB NTCP calculation in chapter 2, the estimated volume 
parameter (n), TD50, and m were 0.41, 43.2 Gy, and 0.31, respectively.  
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1.4 Respiratory Motion of Lung Tumour Volumes 
1.4.1 Respiratory Motion 
 The lungs reside within the thoracic cavity and experience volumetric changes 
during both active and passive breathing.  Respiration, the process of breathing is made 
up of two separate phases, exhalation and inhalation.  During inhalation, active and 
passive, the diaphragm contracts and pulls the lower lung down and forward.  The inter-
costal muscles are involved in the process of inhalation and contract as well, pulling the 
ribs both superiorly and laterally, also increasing the volume of the lungs and thoracic 
cavity.  The increase in lung volume causes changes in air pressure within the lungs.  
Inhalation causes the air pressure within the lungs to drop, drawing in air and allowing 
for gas exchange within the alveoli of the lung.  Non-forced exhalation occurs as a 
passive process caused by the elastic nature of the lung tissue returning to its equilibrium 
position.  As a result of these processes, any tumour volume within the lung will be 
subject to motion due to respiration.  Many studies have focused on the influence of 
respiratory motion on lung tumour movement. Based on this work, the motion of lung 
tumours due to respiratory motion is regarded as extremely complex and patient specific, 
generating a great deal of uncertainty in image-guided radiotherapy for lung cancer [53] 
[54] [55] [56] [57] [58] [59] [60] [61] [62].  At the same time, while literature on the 
effects of respiratory motion continues to grow, the magnitude and general pattern of 
motion influence is still quite variable and unpredictable, as shown in Table 1-3 adapted 
from Keall et al. [63]. 
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Table 1-3: Lung-tumour motion data collected and summarized from selected studies. 
Adapted from Keall et al. [63]. 
Observer(s) Site Direction Average(min.-max.) (mm) Modality 
Ross et al.
62
 Tumour AP 1.0(0-5.0) CT 
  LR 1.0(0-3.0)  
     
Stevens et al.
61
 Tumour SI 4.5(0-22.0) CT 
  SI (moving)              8.3(3.0-22.0) 
    
Shimizu et al.
70
 Tumour AP 6.4(2.0-24.0) CT 
     
Sixel et al.
60
 Tumour SI 6.0(0-13.0) CT 
  AP 2.4(0-4.4)  
  LR 1.2(3.2)  
     
Plathow et al.
63
 Tumour SI 9.5(4.5-16.4) MRI 
  AP 6.1(2.5-9.8)  
  LR 6.0(2.8-9.8)  
     
Ekberg et al.
56
 Tumour SI 3.9(0-12) Fluoro 
  AP 2.4(0-5.0)  
  LR 2.4(0-5.0)  
     
Seppenwoolde et al.
59
 Tumour SI 5.8(0-24.6) Fluoro 
  AP 2.5(0-8.2)  
  LR 1.5(0-2.8)  
     
Barnes et al.
54
 Tumour SI 18.5(9.0-31.9) Fluoro 
     
Giraud et al.
111
 Diaphragm SI 35.0(3.0-95) CT 
     
Ford et al.
92
 Diaphragm SI 20.0(13.0-31.0) Fluoro 
     
Davies et al.
55
 Diaphragm SI 12.0(7.0-28.0) US 
SI: Superior-inferior; AP: Anterior-posterior; LR: Left-right; CT: Computed-tomography; MRI: 
Magnetic resonance imaging; Fluoro: Fluoroscopy; US: Ultrasound 
 
 The motion of the lung tumour is quite complex, with magnitude and pattern of 
motion being dependent on both the disease characteristics and location of the tumour.  
Thus, respiratory motion appears to be a patient-specific problem requiring advancements 
beyond conventional image-guided radiotherapy treatment planning strategies [58] [63].               
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1.4.2 Imaging in the Presence of Respiratory Motion 
 Computed tomography (CT) imaging is the most commonly used imaging 
technique for radiotherapy treatment planning.  As opposed to diagnostic scanning, CT 
imaging involves fast scanning that is typically acquired while the patient breathes freely.  
CT imaging utilizes high-energy x-ray radiation to measure a distribution of linear 
attenuation coefficients within the volume of interest that is being imaged.  These 
attenuation coefficients are then used to create sets of 2D axial, coronal, and sagittal slice 
images of the patient via back projection of x-ray transmission projections through the 
3D volume.  Two types of CT image acquisition are commonly used for radiotherapy.  
Helical scanning acquires image data as the patient is moved through the axial field of 
view (AFOV) while serial scanning requires translation of the patient while acquiring 
information from stationary scan positions at each translation interval.  Images from each 
scan position are integrated to construct 3D volumes [64].  Regardless of the image 
acquisition technique, due to respiratory motion, inherent motion artifacts exist within 
these images predominantly in the form of tumour and diaphragm discontinuities.  
Distortions within the image caused by these discontinuities can have serious 
implications with respect to image integrity.  Accuracy of target volume and normal 
tissue segmentation, dose calculation, and treatment setup registration accuracy can and 
have been known to be affected by respiratory motion artifacts [65] [66] [67] [68] [69] 
[70] [71].  Figure 1-4 and Figure 1-5 depict coronal and sagittal views of a lung cancer 
patient's artifact influenced helical CT scan and the effect of inter-scan artifacts on 
tumour visualisation, respectively. 
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Figure 1-4: Coronal and sagittal views of a lung cancer patient's artifact influenced 
helical CT scan. 
 
Figure 1-5: Top row depicts different artifacts obtained by standard axial CT scanning of 
an object undergoing simulated respiratory motion. These are examples of inter-scan 
artifacts due to depend on the interplay between CT data acquisition and object motion.  
Bottom row depicts true geometry of object as imaged using 4D-CT.  From Rietzel et al. 
[71] with permission from AAPM, College Park, USA. 
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1.4.3 4D-CT Imaging to Address Respiratory Motion-derived 
Uncertainty 
 A method that has become a staple of modern image-guided radiotherapy for lung 
cancer in recent years is four-dimensional CT (4D-CT) scanning.  This image acquisition 
technique has shown the capability to provide artifact-free 3D volumes of thoracic 
volumes regardless of respiratory motion extent.  While slow CT scanning and multiple 
breath-hold CT imaging have been previously suggested to address this problem, 
different issues have arisen with these techniques limiting their usefulness and 
practicality in the clinical setting.  Slow CT scans attempt to average motion of the 
tumour volume over each plane of one or more respiratory cycles. However, it has been 
suggested that breath hold scans at breathing extreme yield superior CT scans.  Breath-
hold scan necessitate longer imaging time, image fusion and segmentation on multiple 
datasets, a factor that limits its clinical viability [72] [73] [74] [75] [76] [77] [78].  Thus, 
larger efforts are currently being applied to the development of 4D-CT acquisition and 
reconstruction, and many approaches now exist for creating a 4D-CT data set, the end 
products of which is typically a series of 3D-CT data sets at multiple phases of the 
patients breathing cycle [79] [80] [81] [82].  This is accomplished by acquiring multiple 
projections of the same anatomical space while free breathing occurs and either sorting 
that projection data (sinogram space) or reconstructed 2D axial slices.  This principle of 
acquisition has been implemented using both helical [79] [81] [83] [84] and serial CT 
[80] [82] [71].  Using helical CT, a low-pitch (ratio of scan table translation to AFOV of 
the scanner), helical scan is used to collect images over a complete breathing cycle at 
each image slice location.  Using serial CT, the couch is fixed during scanning allowing 
for sequential CT images via acquisition of a time series of images over the patient's 
breathing cycle.  As the scan position is fixed, the scanner gantry is continuously rotated 
to acquire the images.  Regardless of acquisition technique, guidance is needed to 
subsequently sort the CT image data based on the breathing pattern.  This requires the use 
of respiratory trace via surrogate marker.  The most common approaches for 
reconstruction of 4D-CT datasets involve using chest/abdominal marker displacement 
[79] [81] [82] [71] or spirometry [80] [85] [86].  External monitoring can also be used, 
however, it is subject to inherent uncertainties involving differences between internal 
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organ motion and external motion [79].   The surrogate data is collected after scanning is 
complete and is used to create respiratory phase bins (~10/breathing cycle).  Images are 
assigned to an individual bin based on a phase tag.  Images within each bin are assumed 
to have been acquired at the same respiratory phase.  These are combined to form a 3D 
volume for each individual respiratory phase.  Complete reconstruction involves the 
creation of a representative 3D volume for each bin, or respiratory phase.  Once this is 
complete, the 3D volumes are then integrated in sequence to form the 4D-CT dataset.  
This method of 4D-CT reconstruction is called retrospective 4D-CT and is the most 
widely used reconstruction method.   
1.4.4 Image Segmentation in 4D-CT 
 Similar to conventional CT-based radiotherapy, 4D-CT based treatment planning 
requires appropriate volume definition, or segmentation of target volumes and OAR's. 
Additional uncertainties inherent to 4D-CT imaging including potential for motion 
artifacts due to irregular breathing patterns and the possibility that a patient's breathing 
pattern may not be accurately represented must also be addressed [87] [88] [89].  Typical 
OAR's for conventional lung-cancer radiotherapy include the esophagus, spinal cord, 
heart and the lungs minus the GTV.  The GTV must be segmented at each respiratory 
phase. The internal gross tumour volume (IGTV) is defined by overlapping all the GTV 
segmentations at different respiratory phases.  This volume is subsequently expanded to 
create the corresponding CTV, with a typical margin of 8mm accounting for microscopic 
disease.  Finally, an additional margin, typically of 5 mm is added to construct the PTV 
that accounts setup uncertainty and possible changes in respiratory motion during the 
course of treatment that are not accounted for during pre-treatment 4D-CT simulation.  
Figure 1-6 shows these margin considerations for respiratory-gated and non-gated 
scenarios. 
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Figure 1-6: 4D-CT derived treatment planning margins for respiratory-gated and non-
gated treatment scenarios. From Wolthaus et al. [84] with permission of Elsevier B.V., 
Amsterdam, AN. 
 
 Respiratory-gated radiotherapy is another option for treatment in patients with 
lung cancer.  Respiratory-gated therapy involves the delivery of radiation to the target 
volume at a subset of breathing phases under the assumption that the tumour moves 
minimally within said phases.  This requires that the radiation beam be only turned on 
when the target volume is in the beam's field of view (FOV).  This technique again 
utilizes respiratory surrogate utilization but allows for treatment of smaller target 
volumes and mitigation of dose to healthy, uninvolved tissue [90] [91].  For respiratory-
gated treatment planning, the IGTV is replaced by a target volume consisting of the GTV 
segmented on an average CT scan made up of CT scans that lie within a specified gating 
window.  
While other motion-encompassing methods to segment target volumes exist such 
as single free-breathing helical CT images, average intensity projection (AIP) images, 
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and fluoroscopy, these strategies have previously been shown to result in treatment 
margins either under- or over-estimating the motion of the tumour, and subsequent target 
volumes [92] [93] [94].  As such, 4D-CT imaging to compensate for respiratory motion 
currently remains the best available solution and has also been shown to be reproducible 
between repeat scans unlike the alternative techniques mentioned above [94].  
1.4.5 Potential Drawbacks of 4D-CT 
4D-CT scanning has been shown to produce image datasets that are typically 
superior to conventional 3D scanning.  However, there are still issues surrounding this 
method of image acquisition, mainly with respect to correlations between respiratory 
surrogates and the patient anatomy and imaging artifacts.  As stated previously, the 
correlation of the respiratory surrogate with the patient’s anatomy is integral to the 
reconstruction of the 4D-CT dataset by labeling the images with the correct respiratory 
phase.  It is extremely important that the respiratory surrogate adequately represents the 
extent of respiratory motion in patients undergoing 4D-CT scanning for radiotherapy 
purposes.  While some studies have found positive correlations between an external 
marker and respiratory motion [95] [96] [97], others have suggested that external markers 
should be avoided as the correlation between markers is inconsistent and a source of 
considerable uncertainty [98] [99].  Other studies have employed methods focused on 
tumour tracking via internal fiducials with internal tracking algorithms [100] and/or 
focused on development of complex respiratory motion prediction algorithms [101] [102] 
to improve the correlation of motion with the respiratory surrogate to avoid image 
artifacts.  However, no consensus yet exists and the relationship between a respiratory 
surrogate and the extent of tumour movement due to respiratory motion remains complex 
and highly variable and dependent on the location of the tumour itself [103].  Further 
analysis of breathing patterns amongst large patient groups has also shown respiratory 
motion to vary not only between patients, but also over time within individual patients 
[104].  This has led to what many refer to as irregular breathing with respect to 
respiratory surrogates.  Studies looking at this effect have shown that the use of 
respiratory surrogates only adequately predicts motion in patients who demonstrate 
regular breathing patterns [105].    
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Imaging artifacts can and most likely will arise in 4D-CT due to unreliable 
respiratory surrogates and a variety of other issues.  These artifacts are similar to those of 
conventional 3D scanning and are a result of merging image data from temporally 
mismatched respiratory phases into a single volume, referred to as inter-scan artifacts.  
While 4D-CT largely mitigates this occurrence, it is not completely eliminated.  In fact, 
even with the improvements in 4D-CT, it has been shown that up to 90% of 4D-CT 
volumes acquired using commercial scanner contain some form of image artifact [106].  
As stated above, inter-scan artifacts in 4D are a result of combining images from different 
respiratory phases of the patient’s breathing cycle.  At times, image reconstruction is 
imperfect and creates inter-scan artifacts in one of three ways, as classified by Yamamoto 
et al. [106].  Yamamoto et al. also demonstrated correlations between artifact severity and 
many other factors including abdominal displacement and irregular breathing patterns 
with the end result being generally the same irrespective of cause for artifact. These 
consequences revolved around GTV and ITV segmentations either over- or under-
estimating the true tumour volume with varying geometric complexity of segmentation 
[106].  Persson et al. [107] found that GTVs contoured artifact influenced respiratory-
phase specific 4D-CT scans were significantly larger than those contoured on artifact 
free, end expiration CT datasets and breath hold scans.   
This is a very serious problem as overly large volumes put healthy, highly 
radiosensitive lung tissue at risk for post-treatment side effects while small margins that 
do not adequately compensate for both disease/tumour extent and motion effects which 
diminishes the efficacy of treatments and does little to cure and/or improve the patient’s 
quality of life.  Currently, clinical practice has accepted that image artifacts will occur 
due to some degree of disassociation between respiratory motion and respiratory 
surrogates.  However, these artifacts themselves play a role in limiting the effectiveness 
of 4D-CT and as such, work must continue to be done to generate more reliable 
respiratory surrogates for patients irrespective of breathing pattern and disease 
characteristics.  
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1.5 Geometric Uncertainty in Radiotherapy 
1.5.1 Image Segmentation and Contouring Uncertainties 
 Radiation therapy is a process involving many steps in sequence from diagnosis to 
treatment, follow-up and assessing patient outcomes.  Each step in the process is linked to 
the next, and uncertainties early on in the process are carried throughout, ultimately 
leading to increased uncertainties in radiotherapy treatment and negative patient 
outcomes.  This necessitates analysis at each stage of the process including their 
downstream effects on the 3D dose distribution and possible biological effects that 
treatment error may result in.  The errors that occur at each stage of radiotherapy can 
collectively be summarized as geometric uncertainties and can be analyzed in terms of 
both the dosimetric and radiobiological effects on treatment outcome.  While there are 
many different individual sources of geometric uncertainty in the radiotherapy treatment 
process, their effects are fairly similar in terms of how they influence the radiotherapy 
treatment outcome.  These uncertainties exist because of variable factors such as the 
relationship between relative positions of the treatment beams, patient anatomy, location 
of the tumour volume during treatment planning and delivery and the overall accuracy of 
radiotherapy.   
While there are many different sources of geometric and non-geometric 
uncertainty ranging from patient positioning to anatomical variations within the patient 
and dose prescription, calculation and treatment delivery, respectively, it has been argued 
that the largest source of error and geometric uncertainty lies in variability in 
segmentation (or delineation) of tumour volumes and normal tissue amongst experts due 
in large part to a lack of knowledge of the exact shape of the lesion, or ground truth, and 
difficulty in defining valid metrics to measure variability [108]. As anatomical 
segmentation is one of the earliest stages of the radiotherapy process, inherent geometric 
uncertainties arise in this process that affect each subsequent stage, potentially 
jeopardizing patient outcomes.   
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1.5.2 Effects of Segmentation Variability 
 A considerable amount of segmentation variability has been reported in 
delineating the GTV in lung cancer for both 3D- and 4D-CT based radiotherapy [109] 
[110] [111] [112] [113].  This variability can at times exceed the clinical margins used in 
construction of the CTV and PTV and results in both geographic miss of the tumour 
volume and/or irradiation of highly radiosensitive healthy lung tissue.  While there exists 
a large amount of research focused on target volume segmentation error in 3D-CT based 
radiotherapy, there has been limited work done on the effects of segmentation variability 
and its downstream effects for 4D-CT based lung cancer radiotherapy.  Louie at al. [111] 
demonstrated that substantial variability in segmentation (or delineation) of tumour 
volumes and normal tissue amongst experts in 4D-CT, but no work currently has been 
done on what role this source of uncertainty plays in post-optimization radiotherapy 
treatment plan integrity, dosimetry and radiobiology.  The effects of segmentation 
variability are important to analyze for two reasons.  First, physicians manually delineate 
target volumes within the 3D image volume and variability of these segmentations 
amongst experts indicates that the degree of visibility within the image is variable enough 
to mislead the trained eye of the physician.   Thus, physicians themselves disagree on 
what exactly constitutes cancer and healthy tissue when viewing CT images.  These 
issues need to be consolidated to ensure consistent and effective treatments irrespective 
of which physician is treating the patient.  Second, segmentation variability can greatly 
affect the effectiveness of the treatment technique that is chosen as the prescription dose 
is optimized to the manually defined target volume for almost all radiotherapy treatment 
strategies.  This means treatment efficacies based on different physician segmentations 
may be affected if large variability exists.  This single source of geometric uncertainty 
can be broken down at the post-treatment planning stages of RT for dosimetric analysis in 
terms of over- and under-dosage to the target volumes and OARs, which is further 
discussed below. 
1.5.2.1 Effects of Under-/over-dosage to Target Volumes 
 Numerous studies for various anatomical locations have been performed showing 
that inadequate target volume segmentation may result in under-dosage to the tumour 
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volume.  Typically, under-dosage results in clinically unacceptable plans, low tumour 
control probabilities, and negation of intended curative efforts.  The issues surrounding 
target over-dosage are slightly more complicated.  Advances in radiotherapy modalities 
over the past decade have led to increased efforts in dose modulation and escalation to 
target volumes.  This has been shown to improve local control and patient outcomes in 
lung cancer radiotherapy [114].  However, the influence of respiratory motion makes 
highly accurate segmentation difficult.  Therefore, target volume over-dosage or dose 
escalation could be advantageous, but in doing this, local control, sparing of normal 
tissue and patient outcomes is largely dependent on mitigation of segmentation-related 
geometric error and variability.  The impact of target delineation, already considered to 
be the largest source of error compared to patient setup and inter/intra-fraction variation, 
takes on an even greater role in radiotherapy as a result. 
1.5.2.2 Segmentation-related OAR Dose Volume Uncertainty 
 Segmentation variability resulting in under-dosage to the target or unnecessarily 
large treatment margins in dose escalation studies can result in higher doses to normal 
tissues and OARs in the vicinity of the tumour volume.  OAR structures in the vicinity of 
lung tumours include the esophagus, heart, spinal cord, healthy lung tissue and 
sometimes the liver.  The esophagus, spinal cord and heart can all be subject to fairly 
large doses of radiation during radiotherapy and are largely independent of the target 
volume segmentation. However, the healthy lung volume is dependent on the target 
volume segmentation as healthy lung is defined as the total lung volume minus the CTV 
[115].  Therefore, segmentation variability can put healthy lung at risk, leading to RILI, 
RP, fibrosis and other side effects.   
1.5.3 Improved Image Segmentation Techniques 
1.5.3.1 Automatic Segmentation and Atlas-based Segmentation 
 In recent years, many strategies have been developed to mitigate the effect of 
segmentation error and inter-/intra-observer effects.  As the current trend towards higher-
level image acquisition and processing continues, volumetric analysis of segmentation, 
whether it is manual or automatic becomes more demanding.  In the context of 
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radiotherapy, it is even more important because 3D dose distribution optimization relies 
upon image segmentation and any segmentation error can put the patient's well being at 
risk.  Additionally, for the physicians who have to segment these volumes, further 
education on emerging technologies and increased time and resources are required to 
adequately perform the task.  As such, many radiological practices have begun to 
incorporate the use of automated and intelligent image analysis and segmentation 
utilizing fundamentals in machine learning and computer vision to achieve highly 
accurate anatomical segmentation that require reduced input from the expert and/or 
physician. 
 
Figure 1-7: Connections between different machine learning processes commonly 
utilized for radiology practices including medical image segmentation and registration, 
computer aided/automated detection and/or diagnosis, and many others.  Adapted from 
Wang and Summers [115] with permission of Elsevier B.V., Amsterdam, AN. 
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 In addition to technological advancements in medical imaging, normal anatomical 
variation, low image contrast, and image artifacts also make manual segmentation a more 
difficult and time-consuming task.  Many computational methods currently exist to 
improve image segmentation and to reduce the clinical workload assumed by physicians.  
The use of such techniques reduces the workload and inherent bias of manual 
segmentation, providing for faster, more robust segmentations with globally coherent and 
smooth surfaces devoid of inconsistencies between image slices inherent to manual 
segmentation [115].   
One of the first and most widely used methods of auto-segmentation is level set-
based segmentation.  Level set-based segmentation uses irregular shapes, object 
topologies, intensities, colours, and/or motion within regions of the image space to guide 
auto-segmentation.  This involves implementing a boundary at the zero-value of a 
hypersurface.  Image information such as grey-scale values and edges are used to drive 
the initial boundary to convergence upon an object boundary [116].  Level sets have been 
used extensively in segmentation of brain, liver, and heart [117] [118] [119] [120] [121] 
[122] [123].   
Another frequently used segmentation technique employs the use of generalized 
Markov chains in multiple dimensions or Markov random fields (MRF).  The MRF is a 
graphical model in which a set of random variables are connected in unidirectional links 
that has been employed for multiple problems in computer vision and image processing 
[124] [125] [126].   From MRF theory, the spatial information within an image volume is 
encoded through contextual constraints of neighbouring pixels or voxels.  These 
constraints can be exploited based on the assumption that neighbouring pixels have either 
the same class labels or similar intensities. This is achieved through characterizing 
mutual influences among pixels using conditional MRF distributions.   The MRF has 
been applied to automatic segmentation in medical imaging by using a maximum a 
posterior (MAP) criterion to solve the model and parameter estimates to control the 
spatial interactions of 2D/3D voxels [124] [127] [128].   
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More recently, graph cut-based segmentation based on the max-flow min-cut 
theorem has been increasingly implemented due to its high level of accuracy, fast 
computation time, and ability to further optimize the segmentation beyond that of what 
level set-based technique can provide [115] [129] [130].  A graph is a representation of 
an object set consisting of nodes and connections between nodes called links.  The nodes 
represent key points of an object set, interconnected nodes represent vertices and the links 
between those nodes are referred to as edges.  The edges represent the spatial relationship 
between different nodes.  Image segmentation is one of the simplest applications of 
graph-cuts.  A cut is a binary partition of the graph itself, in essence labeling the graph.  
Segmentation of an object within the graph can therefore be accomplished by creating a 
graph with vertices corresponding to the image voxels and properly weighted edges.  
Then, by employing a polynomial time minimizing graph-cut algorithm utilizing optical 
flows between nodes, one can segment or extract objects within the image.  This method 
has been used as an improvement upon the MAP-MRF technique to find a globally 
optimal segmentation of image objects among all possible segmentations that satisfy the 
desired contextual constraints [130].  Applications of graph-cuts for segmentation have 
included cardiac, lung, brain, and multiple sclerosis lesions [131] [132] [133] [134] [135] 
[136] [137].   
Model-based segmentation is another technique that has been regarded as one of 
the most successful methods for image analysis and segmentation in recent years [115].  
One implementation of this approach is the use of statistical shape models (SSMs).  
SSMs come in different variants, but, in essence, they all perform the same task.  
Information is gathered regarding common variations of biological objects via training 
shapes, which are then incorporated into the model and analyzed by statistical means to 
guide segmentation.  The most common variants of SSMs are Active Shape Models 
(ASMs) and Active Appearance Models (AAMs).  ASMs work by extracting the average 
shape and a series of variation modes from training data set.  The model is then adapted 
to a new image through a predetermined optimization technique.  A method implemented 
by Cootes et al. [138] [139] adapted to the most prominent edges in the image, however 
this has evolved into the now prominently used AAMs [140].  AAMs are an extension of 
ASMs in that they also incorporate complete appearance or texture information of the 
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object to be segmented, including biological shape variations.  Additionally, they include 
a search algorithm completely different than those of ASMs that incorporates both shape 
and appearance variation into a single linear system.  Other methods aside from ASMs 
and AAMs have also been used.  These techniques are reported on extensively by 
Heimann and Meinzer [141].   
Atlas-based segmentation has been developed in recent years building upon the 
concepts of SSM's in efforts to further improve upon current auto-segmentation 
strategies.   A complete description of neighbourhood relationships between several 
image-based objects is referred to as an atlas [142].  An atlas incorporates locations and 
shapes of anatomical structures, as well as the spatial relationships between them.  The 
atlas itself can be generated by multiple manual segmentations or by integrating 
information from multiple segmented images.  In atlas-based segmentation, an image can 
be segmented by mapping its coordinate space to that of the atlas via image registration.  
This stems from the idea that, given an anatomically correct coordinate mapping from 
image to atlas via registration, the label for each image voxel can be determined by 
looking up the corresponding location in the atlas used for the registration-based 
coordinate mapping [143].  Atlas-based segmentation can also incorporate models such 
as AAMs and ASMs in preliminary stages to establish a degree of similarity between the 
atlas and the image to be segmented, making atlas-based segmentation an easier task.  
This means that the non-rigid registration algorithm will detect smaller magnitudes of 
deformation between image and atlas. This results in less computation time and higher 
accuracy in matching [143] [144].   
 Deformable models are a heavily studied method of model-based image 
segmentation and have demonstrated widespread application in radiology.   Additionally, 
the use of deformable models has demonstrated a great deal of accuracy when dealing 
with respiratory motion influences in CT imaging [145].  It is for this reason that the 
automatic segmentation technique used in Chapter 3 relies upon deformable models.  
Deformable models have demonstrated both the capability to adapt to variability of 
biological structures on both an inter- and intra-patient basis and an ability to auto-
segment structures accurately in the presence of image artifacts [115] [146] [147].  
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Geometric representations of objects are constrained through physical principles to limit 
evolution of volumes of interest and when combined with pattern recognition and 
machine learning techniques provide for robust auto-segmented volumes with optimized 
model parameters and deformation prediction [145].  As such, this technique provides for 
robust segmentation of image-based objects while compensating for biological 
discrepancies and variable image quality.  A summary of applications implementing 
deformable models can be found in the literature review performed by McInerney and 
Terzopoulous [145].  Heimann et al. also performed an extensive study on segmentation 
strategies for the liver [148].  Their study found that multiple segmentation strategies 
were suitable for clinical use and emphasized both that the selection of segmentation 
strategy should depend on segmentation engines capability to handle large datasets and 
the optimal strategy for the anatomy of interest. 
1.5.3.2 Ground Truth Estimation Techniques 
 As techniques in automatic segmentation continue to grow in terms of quantity 
and complexity, the techniques used for analysis, evaluation, and validation of 
segmentation accuracy and efficacy must grow accordingly.  Chalana and Kim [108] 
published a review focusing on the primary challenges facing medical image 
segmentation and the one of the foremost issues was the lack of a definitive gold standard 
or known ground truth segmentations.  They argued that the manual segmentations of 
physicians could not be considered the gold standard due to observer bias and inter-/intra-
observer variability. Deeley et al. not only agreed, but also stated that the inherent 
problem of medical image segmentation itself is the lack of a known ground truth (GT) 
[149].  As such, the need for GT estimation algorithms came to light, as they not only 
provide a reference standard for segmentation variability studies, but they also 
incorporate multiple users segmentation input while mitigating observer bias and 
inter/intra-observer variance.  Biancardi and Jirapatnakul stated that the use of GT 
estimation methods was of value as it allows for estimate segmentations that take into 
account the input segmentations of multiple expert readers and provides for closer 
representation of the tumour volume by minimizing the subjectivity of each observer's 
segmentation [150].  As such, the use of GT estimation methods has grown considerably 
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in recent years and has also been introduced in conjunction with automatic-segmentation 
strategies to produce high quality, high-speed segmentations [151] [152] [153].  The most 
common methods for GT estimation are probability-maps (p-map) and simultaneous truth 
and performance level estimation (STAPLE).  A p-map segmentation of a volume of 
interest is calculated by summing across each observer's binary segmentation or mask 
and dividing by the finite number of observer segmentations in summation.  A binary 
segmentation can be thought of as one where object of interest voxels are assigned a 
value of one, while all other voxels are assigned a value of zero.  Voxel values are in 
essence determined by a weighted average of observer-specific voxel values.  Therefore, 
if 5 observers segment the same volume, and a voxel is labeled as being a part of the 
particular region of interest by 4 observers, its value will equal 0.80.  Subsequent 
thresholding of the probability map to a specific value allows for segmentation of the 
ground-truth estimate.  For example, if a threshold value of 0.50 is selected, voxels 
segmented by 50% of the observers will be included in the segmentation [150] [154].  
Typical threshold values are selected such that threshold ≥ 0.50.   
The STAPLE method was used to formulate consensus/reference segmentations 
for the purposes of this thesis.  This method is fully explained in chapters 2, 3 and 
Appendix A. Figure 1-8 illustrates the implementation of STAPLE as adapted from 
Warfield et al. [155] for prostate periphery segmentation in brachytherapy dose planning. 
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Figure 1-8: Staple implementation in MRI of the prostate, for prostate peripheral zone 
segmentation.  Frequency of assignment of voxels to the prostate peripheral zone in five 
repeated segmentations by the same expert shown in (b) and (c).  The probabilistic true 
segmentation estimated by STAPLE shown in (d). The frequency of selection and true 
segmentation estimate are shown color-coded in proportion to probability of the prostate 
peripheral zone being present at each voxel.  From Warfield et al. [155] with permission 
of IEEE Publishing, New York, USA. 
 
1.6 Techniques and Methodology for Analyzing 
Segmentation Variability 
 In their study on the evaluation of boundary detection algorithms in medical 
imaging, Chalana and Kim also observed that one of the most important issues facing 
medical image segmentation analysis is the difficulty in defining valid metrics for 
analysis due to the complex multidimensional nature of segmentation data that varies 
across different image modalities [108].  Jameson et al. recently performed a review of 
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techniques used in analysis of image segmentation across different anatomies for 
application in image-guided radiotherapy and found that no consistent or widely accepted 
methods for systematic segmentation analysis currently exist [157].  More concerning is 
that they stated that the variability in anatomical segmentation may be largest contributor 
to uncertainty in radiotherapy treatment planning despite the fact that no consensus 
amongst analysis methods appears to exist.  Heimann et al. performed an analysis of 
segmentation techniques for the liver in CT datasets and isolated what they believed to be 
the most important and informative segmentation analysis metrics [148].  These metrics 
mainly focused on two types, volume-based and distance-based.  Deeley et al. shared this 
opinion also in their comparison of manual and automatic segmentations of brain 
structures [149].  Deeley et al. stated that the use of volume metrics provides a suitable 
sense of agreement between two volumes. However, they are fairly insensitive to edge 
differences if those differences have little effect on the overall volume.  Two 
segmentations with large volumes may show high overlap but will have clinically 
relevant differences at the edges of the segmentation.  Crum et al. also stated that a 
shortcoming of volumetric measures is that they provide little information in terms of 
scale of mismatch i.e. possible rotation or deformation [158].  However, volume is still 
the most common metric used in segmentation analysis and when used in conjunction 
with other metrics, can provide for a more complete picture is terms of segmentation 
analysis [148] [149] [159] [157].  Distance measures are used commonly in conjunction 
with volume-based metrics to provide for more thorough analysis.  Distance measures 
allow for compensation of the shortcomings inherent to volumetric measures by 
providing information regarding the differences in segmentations edges and boundaries 
[149].  Volume-based and distance-based metrics chosen for analysis are further 
described in the subsequent chapters of this thesis. 
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1.7 Research Hypothesis 
 This work investigates the hypothesis that evaluating geometric uncertainties that 
arise due to variable image segmentation for 4D-CT based lung cancer radiotherapy can 
lead to the development and refinement of more advanced segmentation strategies 
capable of improving image-guided radiotherapy accuracy and allow for further 
refinement and optimization of treatment techniques.  
1.8 Research Objectives 
 The work presented in this thesis is focused on two main objectives. 
1. Examine the dosimetric and radiobiological effects of tumour volume segmentation 
variability in 4D-CT-based lung cancer radiotherapy 
2. Develop an image segmentation framework capable of mitigating the segmentation-
related geometric uncertainties arising in 4D-CT-based lung cancer radiotherapy. 
 
1.9 Thesis Outline 
1.9.1 Impact of target volume segmentation accuracy and 
variability on treatment planning for 4D-CT based non-small 
cell lung cancer radiotherapy (Chapter 2) 
 While tumour volume segmentation error has been quantified to an extent, the 
effects of this uncertainty on treatment planning in the context of dosimetric and 
radiobiological error have yet to be uncovered.  The work in chapter 2 looks to correlate 
segmentation-related geometric error with dosimetric and radiobiological variance.  This 
study was undertaken using segmentations from 6 radiation oncologists incorporating the 
use of radiotherapy treatment plan scripting to allow for optimization of baseline, 
unbiased radiotherapy treatment plan dose distributions.  Simulated respiratory-gated 
treatment plans were also created to allow for analysis of both gated and non-gated 4D-
CT based radiotherapy treatment plans.  Registration-based analysis and globally 
optimized surface rendering techniques were used to analyze segmentation error.  This 
36 
 
work provides a quantitative evaluation on the correlation between segmentation error 
analysis and dosimetric and radiobiological characteristics of 3D optimized dose 
distributions. 
1.9.2 Consensus-based lung tumour volume auto-segmentation in 
four-dimensional computed tomography imaging (Chapter 3) 
 Chapter 3 presents a novel framework for improved image segmentation in 4D-
CT based lung cancer radiotherapy.  The work in this chapter aims to use consensus-
based segmentation as a way to mitigate inter- and intra-observer variability from tumour 
volume segmentation, and subsequently implement an auto-segmentation technique to 
ease the clinical workload currently being handled by physicians.  Registration-based 
analysis and globally optimized surface rendering techniques were used to quantify 
segmentation accuracy.  This study provides both the framework for an improved 
segmentation workflow and a quantitative analysis on its accuracy in segmenting tumour 
volumes in respiratory motion influenced 4D-CT image datasets.   
1.9.3 Discussion and conclusions (Chapter 4) 
 In the final chapter of this thesis, the main findings of each study are summarized 
and both the experimental and clinical relevance of the work are discussed.  Further 
analyses based on the results of this thesis are subsequently discussed in a section 
dedicated to future work.  The final conclusions of each chapter are tied together and 
presented as a unified whole research investigation. 
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Chapter 2  
2 Impact of target volume segmentation accuracy and 
variability on treatment planning for 4D-CT based non-
small cell lung cancer radiotherapy 
 
2.1 Introduction 
  Accurate target volume definition is of paramount importance in radiation 
treatment planning for non-small cell lung cancer (NSCLC).  Thoracic tumours pose a 
challenge for this as they are characteristically subject to varying magnitudes of motion 
due to respiration [1] [2] [3].  Lung tumours have been shown to move up to 5 cm with 
free breathing [4] and the magnitude of this motion is variable and unpredictable [5].  For 
image-guided radiotherapy (IGRT), conventional three-dimensional CT (3D-CT) imaging 
lacks accurate information on tumour motion, providing images with significant artifacts 
that occur due to changes in tumour shape, volume, and position due to respiratory 
motion [6] [7].  Manual GTV segmentation variability has previously been demonstrated 
for lung cancer in 3D image acquisition [8] [9].  Ancillary measures such as co-
registration with functional/metabolic imaging and/or automatic segmentation strategies 
have been shown to both reduce segmentation variability due to inter- and intra-observer 
[10] [11] [12] [13] [14] [15] [16] [17].  Due to this uncertainty, radiotherapy treatment 
plans based on conventional 3D-CT images are subject to increased target volume margin 
sizes to account for largely misinterpreted tumour locations and subsequent uncertainties 
derived from treatment delivery and organ motion are exacerbated [5].  This fails to 
address the inherent variability of tumour motion on a inter-patient basis and variation in 
tumour geometry on both an inter- and intra-patient basis  and limits local control during 
radiotherapy.   
 Four-dimensional computed tomography (4D-CT) is a technique for image 
acquisition and reconstruction that has emerged in the past decade and is now widely 
used in radiation therapy of thoracic volumes [18] [19] [20] [21].  4D-CT imaging allows 
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one to better capture information about changes in tumour shape, volume, and location 
associated with respiratory motion in CT image datasets.  Several methods exist to 
facilitate 4D-CT acquisition and reconstruction. However, the end result typically 
consists of multiple 3D-CT datasets at multiple phases of the patients breathing cycle.  
The most reliable method for target volume segmentation in 4D-CT consists of 
delineating the gross tumour volume (GTV) on each respiratory phase based CT dataset 
(typically 8-12 phases) with a subsequent internal gross tumour volume (IGTV) created 
by combining multiple GTV segmentation into one enveloped volume.  The GTV-CTV 
margin expansion of typical 3D-CT based radiotherapy remains the same, however, it is 
applied to the IGTV to create the internal target volume (ITV) to account for microscopic 
disease.  Although methods currently exist to expedite the segmentation of the IGTV in 
4D-CT datasets [14] [15] [16] [17] [22] [23] [24], the most reliable method for 4D-CT 
target volume segmentation is still manual segmentation of the GTV for all respiratory 
phases and subsequent margin expansions for the ITV and planning target volume (PTV) 
[25].  For treatment planning purposes, the PTV requires a margin expansion of 5-10 mm 
upon the ITV to include for setup uncertainty and intra-fraction respiratory motion.  In 
the context of lung cancer radiotherapy based on 4D-CT, the information from all 
respiratory phases of the 4D-CT dataset can be incorporated in target volume 
segmentation, or a small subset of the 4D-CT respiratory phase datasets can be used that 
represent the optimal, most stable portion of the breathing cycle during which to segment 
the target volume for treatment purposes.  Subsequently, the treatment beam is activated 
during this portion of the respiratory cycle for subset-based target volumes.  This method 
is referred to as respiratory-gated radiotherapy.  The IGTV then consists of GTV 
segmentation across the intended gating window, as determined by some form of 
respiratory trace.  Subsequent treatment margins and typical prescription doses remain 
the same as those used for treatment planning based on the entire 4D-CT dataset.  The 
goal of respiratory gating is to minimize the beam on time during period of extreme 
respiratory motion.  Manual target volume segmentation therefore consists of GTV 
segmentation on 3 or 4 respiratory phases as opposed to the complete dataset.     
 While manual delineation is both reliable and accurate, it is time consuming and 
subject to considerable amounts of inter- and intra-observer variability.  Examples of this 
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variability can be seen in Figure 1.  More recently, geometric uncertainties due to target 
volume segmentation have been explored in the joint context of 4D-CT imaging and lung 
cancer [26] [27] [28] [29] [30].  These studies have shown improvements over 
conventional 3D-CT for mitigating uncertainty.  While techniques for improved 
segmentation and analysis of the effects of respiratory motion in the context of lung 
cancer are extremely valuable in addressing this issue, the need to quantify variability and 
accuracy at the treatment planning stage is equally important in measuring the dosimetric 
variability due to segmentation-related geometric uncertainties.  If the variability of 
anatomical segmentation exceeds the margin sizes applied to target volumes, the potential 
for geographic miss of the tumour volume and/or irradiation of normal tissues and OARs 
can be expected to increase.  Conversely, if current clinical margins are overly 
conservative in addressing geometric uncertainties, increased normal tissue irradiation 
can mitigate the effects of targeted radiotherapy and impact patient outcomes negatively 
due to radiation induced lung injury (RILI) and/or secondary malignancies.  As very little 
literature exists on the dosimetric impact of target volume segmentation variability in 4D-
CT based NSCLC radiotherapy, this work aims to examine the impact of tumour volume 
segmentation accuracy and variability for intensity-modulated radiation therapy (IMRT) 
treatment planning for NSCLC in terms of segmentation accuracy and quality, as well as 
subsequent treatment plan dosimetry and radiobiology.  To do this, treatment plans based 
on multiple expert segmentations across a series of 4D-CT patient datasets have been 
compared to plans based on reference gold standard volumes for simulated respiratory-
gated and non-gated treatment planning scenarios.  Segmentation variability is assessed 
as well as optimized dose distributions in terms of both physical and radiobiological dose 
characteristics in hopes of quantifying segmentation-related geometric uncertainties 
based on various clinical endpoints at the treatment planning stages of radiotherapy. 
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(i)                                                                 (ii) 
    
(iii)                                                                 (iv) 
Figure 2-1: Representative slices in the axial, sagittal, and coronal planes and 3D view of 
6 physicians manual GTV segmentation on all 10 respiratory phases for patients B, E, F, 
and H, in panels (i) through (iv), respectively. 
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2.2 Methods and Materials 
2.2.1 Image Acquisition and Reconstruction 
 4D-CT imaging was performed on ten patients with NSCLC, with patient 
demographics and disease information is presented in Table 1.  Local REB approval was 
obtained and all data was anonymized prior to segmentation.  A Philips 16-slice 
Brilliance Big Bore CT scanner (Philips Medical Systems, Cleveland, USA) was used 
with pulmonary gating application to image patients.  The Real-Time Position 
Management (RPM) respiratory gating system (Varian Medical Systems, Palo Alto, 
USA) was used as a respiratory surrogate.  The RPM system uses an infrared camera that 
follows reflective markers placed on the patient's chest or abdomen.  For all ten patients, 
a long spiral CT scan with pitch < 0.1 was performed to cover the entire thorax.  
Pulmonary signal data was collected from the RPM system simultaneously with CT data.  
CT data was then reconstructed at ten different respiratory phases (i).  Respiratory phases 
were tagged as percentage of full inspiration, indicating temporal steps from one full 
inspiration phase to another (i = 0, 10,..., 90%).  This form of image reconstruction 
allows for visualization of tumour volume displacement at ten equidistant points in time 
throughout the respiratory cycle.  Due to this 4D reconstruction method, for all patients 
the phases (i) correspond to each other. 
 
Table 2-1: Patient demographic, disease information, and manual segmentation 
difficulty. 
Patient Staging MSD* **Location Volume (cm3) 
A IIIA 3.00 (Difficult) RLL 272.63 
B IIIA 4.50 (Difficult) RLL 67.70 
C IIB 3.00 (Difficult) RLL 29.86 
D IIIA 1.83 (Easy) RLL 46.99 
E IIIA 1.33 (Easy) LLL 10.42 
F IIB 3.50 (Difficult) RUL 17.95 
G IIIA 2.17 (Easy) LUL 2.24 
H IIIA 3.33 (Difficult) LUL 20.80 
I IIB 1.83 (Easy) RLL 28.18 
J IIIA 2.50 (Easy) RUL 90.10 
*MSD: Mean Segmentation Difficulty    
**Location of primary tumour volume   
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2.2.2 Manual Segmentation 
 The GTV was segmented on each of the ten respiratory phases for ten patients by 
six radiation oncologists at the London Regional Cancer Program (LRCP) with clinical 
experience ranging from 1 to 25 years.  Manual segmentation was performed based on 
blinded radiological reports and difficulty was ranked from 1 (least difficult) to 5 (most 
difficult) for each case by each observer (Table 1).  Target volume segmentation was 
performed using the Pinnacle Treatment Planning System (Philips Radiation Oncology 
Systems; Milpitas, USA).  Default visualization parameters were used for lung tumour 
segmentation by all physicians in accordance with recommendations by Giraud et al. [8] 
(-600/1600 HU for lung window, +20/400 HU for the mediastinal window).  The IGTV 
envelope, defined as the union of GTV segmentation from all respiratory phases was 
created using MiMVista v.5.2 (MiM Software, Cleveland, USA).  Nodal volumes were 
also present for eight out of ten patients and were segmented by physicians similarly to 
the GTV to allow for construction of a Nodal ITV, Nodal PTV and a Total PTV (Primary 
+ Node(s)) at the treatment planning stage.  Experts were blinded to one another's 
segmentations and were provided with a representative axial 2D CT image indicating 
location of the primary GTV and specific node(s).  For simulation of respiratory gating, 
manual GTV segmentations from respiratory phases within the gating window (Typically 
the 30-60% or 40-70% phases) were fused to create the IGTVSubset upon which clinical 
margin expansions were applied.  For non-gated scenarios, manual GTV segmentations 
from all respiratory phases were fused to create IGTVFull upon which clinical margin 
expansions were applied.  OARs were segmented by a single observer in accordance with 
the 1993 ICRU Report #62 to allow for a standardized interpretation amongst observers.   
2.2.3 Reference Segmentation 
 The STAPLE algorithm has been shown to be both highly robust and adept at 
incorporating and fusing multiple expert segmentations into one GT estimate 
segmentation (multi-expert GT segmentation) [31].  The STAPLE technique, proposed 
by Warfield et al. [32], takes a collection of J binary image segmentations as inputs and 
simultaneously computes a probabilistic estimate of the true tumour segmentation and a 
measure of the performance level of each observer's input segmentation.  Segmentation 
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information is available as decision dij, indicating the label given by each expert j for 
each voxel i.  The goal of STAPLE is then to estimate the ground truth (GT), or reference 
standard segmentation T, and the parameters that describe the agreement between experts 
and the GT estimate given by   , … ,  , … , .  Each parameter   is an    
matrix, where N is the number of labels in the segmentation, and ′ is the probability 
that expert j gave the label s' in the voxel i when the reference standard label is given by 
s, for example: ′    ′  .   
The algorithm utilizes an expectation-maximization approach to improve the 
initial GT estimate in an iterative fashion.  In the E-step, the unobserved true 
segmentation is computed as a probability map where each voxel is assigned a 
probability of being a part of the segmented object (tumour volume).  This involves 
estimating the conditional expectation of the complete data log likelihood function given 
by |!" (where k is the iteration number) knowing the expert parameters at each 
previous iteration: !.  This requires the knowledge of the posterior probability of : |$, !", which then allows for the maximization step.  In the M-step, observer's 
performance level parameters are estimated at iteration % & 1, given by !(" by 
maximizing the complete data log-likelihood using the current reference segmentation 
generated at the E-step.  Performance parameters are based on sensitivity and specificity 
estimators, which correspond to the degree to which voxels are correctly predicted to be 
or not to be a part of the GT, respectively.  Initial values for sensitivity and specificity 
can be given in some cases or they can be approximated by comparing individual 
segmentations to a segmentation comprised of all observer segmentations with a majority 
vote.   
In this study, all observers were assigned the same initial sensitivity and 
specificity as their true explicit segmentation quality is unknown, as per suggestions 
made by Warfield et al.  The final step of the STAPLE algorithm is the generation of the 
final estimate of GT based on the construction of a hidden Markov Random Field (MRF).  
In this step, the relationships between voxels and their neighbors are used to regularize 
the EM estimate and the finding of the optimal solution or final estimate is a max-flow 
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min-cut problem with a modified implementation of the work by Boykov and 
Kolmogorov [31] [32] [33] [34].  In using the STAPLE algorithm for GT estimation, it is 
important to remember that the algorithm itself benefits from prior information made 
available by way of input segmentation reliability.  This means that the performance of 
the GT estimate relies on the level of expertise of each observer, where the input 
segmentation is used to formulate the GT estimate.  As such, manual segmentations of 
the six participating physicians were incorporated into multi-expert ground truth 
estimates via STAPLE to create reference standard segmentations in this study.  This 
method allows for comparison of both target volume segmentations and corresponding 
treatment plan dose distributions to a gold standard with equal bias assumed towards each 
observer.  Reference target volumes were constructed for both gated and non-gated 
scenarios with the same clinical margins applied as manual segmentations.       
2.2.4 IMRT Treatment Planning 
 The PinnacleTM (Pinnacle; Milpitas, USA) treatment planning system (TPS) was 
used for Intesity-Modulated Radiation Therapy (IMRT) treatment planning and dose 
distribution calculation.  Treatment planning was automated using in-house scripts 
written in the PinnacleTM scripting language [35].  The collapsed cone convolution 
algorithm was selected in Pinnacle software to compute the 3D dose matrix with 4 mm 
grid spacing.  Treatment planning DVH objectives were chosen to comply with RTOG 
criteria (Trial 0617) with a fixed 5-beam arrangement at 6 MV energies. Gantry angles 
were determined on a patient-specific basis in efforts to achieve plans compliant with 
RTOG 0617 [36].  The target prescription dose was 60 Gy in 30 fractions normalized to 
100% at the target’s centroid.  Target coverage was assessed using D95 of the PTV 
volumes (PTV-Primary, PTV-Nodes, and PTV-Total) during treatment planning to 
ensure adequate target coverage.  While RTOG 0617 calls for assessment of target 
volume coverage in terms of the PTV-Total, this constraint was also applied individually 
to both PTV-Primary and PTV-Nodes to ensure all targets were sufficiently covered 
during dose calculation and optimization.  Dosimetric constraints as outlined by RTOG 
0617 are shown in Table 2. 
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Table 2-2: Dosimetric constraints used for treatment planning 
Organ Constraint 
PTV total  D95 ≥ Prescription Dose 
(Primary + Nodes) Dmin > 5700 
 Dmax < 7200 
Total Lung V20 < 37% 
 
MLD ≤ 2000 
Spinal Cord Dmax < 5050 
Esophagus Mean Dose < 3400  
Heart V60 < 33% 
 V45 < 66% 
 V30 < 100% 
 
2.2.5 Segmentation Comparison 
Manually derived, physician segmentations were compared to the STAPLE 
segmentations for Primary and Nodal PTVs for all ten patients in both gated and non-
gated scenarios.  The volume overlap error (VOE) was chosen to compare segmentation 
volumes in this study.  This metric is given as a percentage and is defined as: 
)*+  ,1 - .)/ 0 )1)/ 2 )134  100% (1) 
 The VOE is dependent on the ratio between the intersection and union of the two 
segmented volumes, otherwise known as the Jaccard Index or Tanimoto coefficient [37] 
[38].  This metric was chosen in accordance with studies performed by Heimann et al. 
and Fotina et al. who observed both the popularity of the metric and it's superiority in 
comparison to other volume-based metrics in the context of segmentation analysis, 
respectively [39] [40].  A value of 100% represents complete disagreement between 
volumes, while a value of 0% represent perfect volumetric overlap.  A distance-based 
metric for segmentation accuracy was also used in this study to evaluate potential 
differences in segmentations based on shape and/or surface deviations undetectable by 
way of volume-based measures.  Jameson et al. summarized many current methods for 
calculating distance-based evaluation metrics for segmentation analysis [41].  For this 
study, the root mean square (RMS) symmetric surface distance was calculated as it 
represents the average error measures between segmentations.  The RMS symmetric 
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surface distance is measured in millimeters (mm) and is based on surface voxels of two 
separate segmentations, whose surfaces are given by S(A) and S(B), and point clouds 
representing segmentations given by A and B, respectively.  This is done by calculating 
and storing the squared Euclidean distance between each set of corresponding points.  
The average RMS symmetric distance is then defined as the average of all stored 
distances, where 0 represents a perfect segmentation.  Formally, the distances between 
corresponding points in S(A) and S(B) is given by /, 7", and 1, 8"", 
respectively.  The RMS symmetric distance is then given by:  
9:$8, 7"  ;< 1|8"| & |8"|=
 ;< > ?/, 7" & > ?1, 8"@AB1"CAB/" = 
(2) 
 
 The RMS symmetric distance highly correlates with the average distance.  
However, by squaring the distances between points, larger deviations between surfaces 
are punished stronger.  As stated by Heimann et al., this metric is one of the most 
important in evaluating segmentation accuracy [39]. 
 
2.2.6 Treatment Plan Comparison 
 Treatment plans were optimized for all observer-based target volume 
segmentations and STAPLE segmentations for primary and nodal (if present) targets in 
gated and non-gated scenarios.  Observer-based treatment plan dose distributions were 
then analyzed in the context of the STAPLE segmentation i.e. observer-based dose 
distributions overlaid on STAPLE segmentations.  This was done to assess variable 
dosimetry inherent to each physician's target volume segmentation against optimal 
dosimetry calculations based on those of the GT estimate.  Several measures were used to 
assess the quality of treatment plan dose distributions.  Metrics representative of both 
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physical and radiobiological dosimetric characteristics were used to quantitatively 
evaluate the variability of target volume segmentation for NSCLC radiotherapy.  
 In assessing the physical characteristics of optimized dose distributions, the DVH 
allows for dosimetric evaluation of treatment plans, including the dose (Gy) received by 
X% of a particular structure's volume (D[volume]), and/or the relative volume (%) 
receiving at least X dose (V[dose]).  Using these values, analysis of the dose distribution 
in terms of dose homogeneity/heterogeneity throughout the target volume was performed.  
The homogeneity of the dose within the GT estimate target volume based on the 
physicians optimized dose distribution was calculated using the homogeneity index (HI) 
given by  
DE  $FGH - $FI$J  100%, (3) 
where DP is the prescription dose, and Dmax and Dmin are the doses for 1% and 99% of the 
target volume, respectively.  Dose uniformity within the target volumes was assessed by 
way of the uniformity index (UI), which is defined as the ratio of the D5 to the D95. 
KE  $L$ML (4) 
These dimensionless parameters were chosen for this study following methodologies for 
assessing the quality of target volume coverage of treatment plans established in prior 
dosimetric evaluation studies [42] [43] [44] [45] [46]. 
Radiobiological parameters for assessment in this study included the primary 
tumour control probability (TCP) and the normal tissue complication probability (NTCP) 
for the healthy lung (defined as lung minus CTV-primary per RTOG 0617).  TCP 
calculations were performed based on Poisson statistics, assuming a logistic dose-
response curve analogous to prior work [47] [48] as follows:    
N  O1 & .$LP$ 3
QRS, (5) 
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where D represents the dose to the target sub-volume, D50 is the dose required for a 50% 
TCP and γ is the normalized slope of the sigmoidal dose response curve.  For TCP 
calculations, a D50 of 70 Gy, a γ of 2.0 were assumed and an 	
 = 10.  TCP calculation 
for this study did not take into account dose inhomogeneties within the target sub-
volume.  Parameters for TCP calculations were chosen in accordance with the study 
performed by van Baardwijk et al. [49].  For NTCP calculations, the Lyman-Kutcher-
Burman (LKB) model was used [50] [51] [52].  From the LKB model, the NTCP can be 
described via three equations.  The effective dose to an OAR is defined as: 
$TUU  V> W · $" I⁄ Z
I, (6) 
where Di is the dose relative to the sub-volume vi, describing the bins of the differential 
dose-volume histogram, and n is the parameter describing the magnitude of the volume 
effect.  When n = 1, this expression is equal to the mean lung dose (MLD).  However, for 
this study, the estimated volume parameter was n = 0.41 as per the study by Tucker et al. 
who showed it better predicted RILI risk compared to the MLD (n = 1) [53].  If the Deff 
(or equivalent uniform dose (EUD)) is distributed uniformly throughout the entire 
volume, it will yield an equivalent NTCP as the actual non-uniform dose distribution.  
Subsequently, the NTCP is calculated using the Deff and an additional parameter, t, 
defined as: 
[  $TUU - $LP\ · $LP  (7) 
Yielding the expression for NTCP as follows: 
N  1√2_ · ` a

b
c
d (8) 
For NTCP calculations, additional parameters of m = 0.31, and TD50 = 43.20 Gy were 
used, again in accordance with the study by Tucker et al. [53].  As previously stated, 
GTVs were manually segmented on 4D-CT data sets for both respiratory-gated and non-
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gated scenarios by 6 different radiation oncologists.  However, PTV segmentations (GTV 
+ 1.5cm) were compared and planned upon to provide insights into accuracy of treatment 
planning target volumes and subsequent dosimetric variability.  As such, different 
segmentations were compared to STAPLE derived segmentations with precisely the same 
margins to avoid any systemic errors in segmentation analysis and treatment plan 
comparison.        
 Differences between respiratory gated and non-gated treatment plan dose 
distributions were assessed with the Wilcoxon matched-pair signed rank test.  This test 
allowed for non-parametric comparison with small sample sizes. 
 
2.3 Results 
2.3.1 Segmentation Variability 
 All manual segmentation results were compared to their respective STAPLE GT 
estimate segmentations in evaluating segmentation accuracy and quality.  Figure 2-2 
shows mean observer intra-patient VOE for primary and nodal GTV volumes and their 
respective intra-patient standard deviations (SD) in respiratory-gated and non-gated 
scenarios for all ten patients. For non-gated primary GTVs, mean observer VOE ranged 
from 8.96 i 0.56% to 35.64 i 7.50%, with SD ranging from 0.56% to 13.17%.  Non-
gated nodal GTV demonstrated mean observer VOE ranging from 16.35 i 1.49% to 29.08 i 4.13% with SD ranging from 1.49% to 13.14%.  For respiratory-gated primary 
GTVs, mean observer VOE ranged from 8.78 i 3.04% to 35.09 i 9.75%, with SD 
ranging from 2.26% to 11.57%.  Gated nodal GTVs demonstrated mean observer VOE 
ranging from 12.25 i 2.86% to 24.62 i 12.74% with SD ranging from 2.86% to 13.21%.   
Figure 2-3 shows mean observer symmetric RMS distances for primary and nodal 
GTV segmentations compared to STAPLE segmentations with respective standard 
deviations (SD) in respiratory-gated and non-gated scenarios for all patients.  For non-
gated primary GTVs, mean observer RMS symmetric distances ranged from 3.42 i
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0.36mm to 7.75 i 1.84mm, with SD ranging from 0.18mm to 1.88mm.  Non-gated 
nodal GTVs demonstrated mean observer RMS symmetric distances ranging from 4.11 i 0.75mm to 6.48 i 0.66mm with SD ranging from 0.16mm to 3.20mm.  For 
respiratory-gated primary GTVs, mean observer RMS symmetric distances ranged from 3.37 i 0.61mm to 7.94 i 1.49mm, with SD ranging from 0.23mm to 1.95mm.  Gated 
nodal GTVs demonstrated mean observer symmetric RMS distances ranging from 3.37 i 0.79mm to 5.59 i 0.87mm with SD ranging from 0.40mm to 3.21mm.  
Nodal GTV segmentation was typically subject to larger errors and variance in 
terms of both VOE and RMS symmetric distances, however, the variability was still quite 
high for both target volumes across the observer group.  Wilcoxon matched-pair signed 
rank tests demonstrated no statistically significant differences between gated and non-
gated target volume segmentations with respect to either accuracy metric. 
 
Figure 2-2: Mean observer VOE for primary and nodal GTV volumes and their 
respective standard deviations (SD) in respiratory-gated and non-gated scenarios for all 
ten patients. 
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Figure 2-3: Mean observer symmetric RMS distances for primary and nodal GTV 
segmentations compared to STAPLE segmentations with respective standard deviations 
(SD) in respiratory-gated and non-gated scenarios for all patients. 
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2.3.2 Dosimetric Variability 
 Figures 2-4 to 2-8 demonstrate the subsequent effects of variable target volume 
segmentation on treatment planning for a moderately variable case (patient F).  Figure 2-
4 demonstrates PTV definition for multiple physicians as well as the STAPLE-based 
PTV estimate for respiratory-gated (a) and non-gated scenarios (b), respectively.  The 
subsequent dose distributions from each target overlaid on the GT estimate segmentation 
are shown in Figures 2-5 and 2-6 with segmentations corresponding to those in Figure 2-
4.  The DVH curves for each physician are subsequently shown in 2-7 and 2-8. 
 
Figure 2-4: Variable target volume definitions for multiple physicians as well as the 
STAPLE-based PTV estimates for patient F in respiratory-gated (a) and non-gated 
scenarios (b), respectively. 
 
 The D95 for primary and nodal PTVs in both respiratory-gated and non-gated 
scenarios is shown in Figure 2-9.  Non-gated primary GTV segmentations across the 
observer segmentation groups yielded only 4 cases in which clinically acceptable target 
volume coverage was achieved ($ML  60Gy) (Patients A, E, G, J).  Nodal GTV 
segmentations across this group yielded only one case in which mean observer 
segmentations provided for clinical acceptable target coverage (Patient J).  For 
respiratory-gated primary GTV segmentations, again only 4 cases provided for clinically 
acceptable target volume coverage (Patients A, D, G, J), while only one case provided 
clinically acceptable nodal GTV coverage (Patient J).  Mean D95 demonstrated relatively 
similar target volume coverage between respiratory-gated and non-gated treatment plans.   
 Figure 2-5: Radiotherapy treatment plan dose distribution isodoses
volume segmentations for patient F
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Figure 2-7: DVH curves for normal lung and primary PTV based on multiple observers 
for the non-gated scenario for patient F.   
 
 Figure 2-10 shows mean uniformity indices (UI) for primary and nodal GTVs in 
both respiratory-gated and non-gated scenarios compared to STAPLE segmentation-
based UI. For non-gated primary GTVs, mean observer UI ranged from 1.07 i 0.1 to 1.93 i 0.90, with SD ranging from 0.01 to 0.90.  Non-gated nodal GTV demonstrated 
mean observer UI ranging from 1.08 i 0.06 to 1.88 i 0.79 with SD ranging from 0.02 
to 0.79.  For respiratory-gated primary GTVs, mean observer UI ranged from 1.07 i0.02 to 2.21 i 0.89, with SD ranging from 0.01 to 0.89. Gated nodal GTVs 
demonstrated mean observer UI ranging from 1.08 i 0.02 to 1.42 i 0.34 with SD 
ranging from 0.02 to 0.61. 
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Figure 2-8: DVH curves healthy lung and primary PTV based on multiple observers for 
the respiratory-gated scenario for patient F. 
 
 Dose uniformity was consistently worse amongst observers compared to the 
STAPLE derived target volume dose distributions.  Nodal GTV segmentation typically 
provided for slightly increased UI and associated variance, indicative of higher 
segmentation uncertainty being propagated into the treatment planning stage.  Figure 2-
11 shows mean homogeneity indices (HI) for primary and nodal GTVs in both 
respiratory-gated and non-gated scenarios compared to STAPLE segmentation-based HI.  
For non-gated primary GTVs, mean observer HI ranged from 11.44 i 2.35% to 61.11 i26.54%, with SD ranging from 2.07% to 26.54%.  Non-gated nodal GTV demonstrated 
mean observer HI ranging from 13.35 i 9.15% to 75.15 i 4.70% with SD ranging from 2.01% to 27.64%. 
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Figure 2-9: Mean D95 for primary and nodal GTVs based on observer segmentations as 
well as D95 from STAPLE-based treatment plan in both respiratory-gated and non-gated 
scenarios for patient F. 
 
 For respiratory-gated primary GTVs, mean observer HI ranged from 10.68 i1.90% to 74.03 i 31.32%, with SD ranging from 1.90% to 31.32%.  Gated nodal 
GTVs demonstrated mean observer HI ranging from 11.34 i 3.38% to 53.99 i 25.95% 
with SD ranging from 3.38% to 25.95%.  Dose homogeneity reflects a similar trend 
demonstrated in UI measurements with greater sensitivity and magnitude of deviation.  
Nodal GTV segmentations provided for increased variability and uncertainty in 
optimized dose distributions compared to Primary GTVs.  However, the magnitude of 
variation varied between physicians on an inter-patient basis, most noticeable for patient 
B (extremely variable) and patient E (minimal variance).  Variability was largely 
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inconsistent for both metrics, however, trends demonstrated for segmentation-based 
analysis were reflected in subsequent dosimetric analysis for corresponding patients 
indicating that target volume segmentation variability influences dosimetric uncertainty 
and fluctuates on both an inter-physician and an inter-patient basis.  Wilcoxon matched-
pair signed rank tests demonstrated no statistically significant differences between gated 
and non-gated target treatment scenarios with respect to dosimetric measures.    
 Figure 2-12 shows mean tumour control probabilities (TCP) based on treatment 
plans for each physician’s primary GTV segmentations as well as the TCP derived from 
STAPLE-based treatment plans for both respiratory-gated and non-gated scenarios.  
Mean observer-based TCPs were again subject to a wide range of variability and were 
typically lower than that of the STAPLE-based TCP for both scenarios.  For non-gated 
primary GTVs, mean observer TCPs ranged from 22.60 i 11.86% to 33.66 i 0.59%, 
with SD ranging from 0.52% to 11.86%.  For respiratory-gated primary GTVs, mean 
observer TCPs ranged from 18.44 i 7.83% to 33.96 i 1.30%, with SD ranging from 0.42% to 7.83%.  Wilcoxon matched-pair signed rank tests demonstrated no statistically 
significant differences between gated and non-gated target treatment scenarios with 
respect to TCP.     
 All treatment plans were able to meet RTOG 0617 standards for all critical 
structures (Spinal Cord, Esophagus, Heart, Healthy Lung).  OAR analysis focused on the 
total lung volume as it is directly related to target volume segmentation variability unlike 
the other critical structures present during treatment planning.  Total lung was assessed 
based on the dose to the total lung minus the CTVPhysician overlaid on the total lung minus 
CTVSTAPLE for each physician's respective treatment plan dose distributions.  Table 2-3 
and Table 2-4 show mean total lung dosimetric measures across the physician group iSD" compared to those derived from the STAPLE-based dose distribution for 
respiratory-gated and non-gated scenarios, respectively. 
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Figure 2-10: Mean UI for primary and nodal GTVs based on observer segmentations as 
well as UI from STAPLE-based treatment plan in both respiratory-gated and non-gated 
scenarios. 
 
 Very little variation is present on an intra-patient basis, with inter-patient 
fluctuation occurring most likely as a result of varying GTV size.  Figure 2-13 shows 
mean normal tissue complication probabilities (NTCP) based on treatment plans for each 
physicians as well as the NTCP derived from STAPLE-based treatment plans for both 
respiratory-gated and non-gated scenarios. No discernible trends are present and 
variability appears to be patient-specific.  Wilcoxon matched-pair signed rank tests 
demonstrated no statistically significant differences between gated and non-gated target 
treatment scenarios with respect to NTCP.    
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Figure 2-11: Mean HI for primary and nodal GTVs based on observer segmentations as 
well as HI from STAPLE-based treatment plan in both respiratory-gated and non-gated 
scenarios. 
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Figure 2-12: Mean TCP for primary and nodal GTVs based on observer segmentations 
as well as TCP from STAPLE-based treatment plan in both respiratory-gated and non-
gated scenarios. 
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Figure 2-13: Mean NTCP for primary and nodal GTVs based on observer segmentations 
as well as NTCP from STAPLE-based treatment plan in both respiratory-gated and non-
gated scenarios. 
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Table 2-3: Dosimetric measures for lung in simulated respiratory-gating plans. 
Respiratory-gated Plans             
Patient V10 (%)   V15 (%)   V20 (%)   V30 (%)   MLD (Gy)  
 
Physicians STAPLE  Physicians STAPLE  Physicians STAPLE  Physicians STAPLE  Physicians STAPLE 
Patient A 63.26 ± 3.59 65.38  40.84 ± 1.76 41.34  31.07 ± 1.26 31.53  21.05 ± 0.91 20.92  19.67 ± 0.49 19.61 
Patient B 52.14 ± 5.50 56.06  33.57 ± 5.61 35.84  25.00 ± 4.84 27.27  11.25 ± 4.45 12.69  14.47 ± 2.25 15.53 
Patient C 45.64 ± 5.33 51.65  28.85 ± 3.61 31.66  21.74 ± 2.84 24.27  9.23 ± 2.06 11.24  13.09 ± 1.23 14.46 
Patient D 34.71 ± 1.22 37.93  26.90 ± 0.64 27.56  24.55 ± 0.58 25.14  18.45 ± 0.46 18.86  13.59 ± 0.38 14.10 
Patient E 32.09 ± 2.15 33.59  24.74 ± 0.75 25.26  22.35 ± 0.49 22.87  16.72 ± 0.55 17.29  12.28 ± 0.49 12.63 
Patient F 38.68 ± 2.74 37.79  29.57 ± 1.83 29.95  23.92 ± 1.42 24.67  18.16 ± 0.83 18.04  14.07 ± 0.74 14.20 
Patient G 45.53 ± 4.14 44.55  35.56 ± 2.50 35.38  27.92 ± 2.66 27.46  13.05 ± 3.05 12.54  13.70 ± 1.18 13.64 
Patient H 35.52 ± 2.85 37.29  26.65 ± 1.9 27.93  24.19 ± 1.63 25.06  19.45 ± 1.23 19.91  14.17 ± 0.89 14.74 
Patient I 31.69 ± 2.01 35.10  24.01 ± 1.53 26.16  20.02 ± 1.35 21.66  10.46 ± 0.93 11.23  11.13 ± 0.73 11.21 
Patient J 31.82 ± 2.28 31.13  27.44 ± 1.97 26.88  24.23 ± 1.69 23.78  15.62 ± 1.16 14.60  11.63 ± 0.75 11.30 
 Table 2-4: Dosimetric measures for lung in simulated non-gated plans. 
Non-gated Plans             
Patient V10 (%)   V15 (%)   V20 (%)   V30 (%)   MLD (Gy)  
 Physicians STAPLE  Physicians STAPLE  Physicians STAPLE  Physicians STAPLE  Physicians STAPLE 
Patient A 60.61 ± 2.92 66.43  39.31 ± 0.94 42.41  30.23 ± 0.93 31.87  20.51 ± 1.09 21.47  19.34 ± 0.56 19.906 
Patient B 49.49 ± 6.76 54.64  30.79 ± 5.78 33.87  22.74 ± 4.86 25.44  11.23 ± 4.70 13.12  14.03 ± 2.33 15.347 
Patient C 49.26 ± 2.57 53.86  30.21 ± 1.19 33.02  22.57 ± 1.40 25.25  9.85 ± 1.20 12.83  13.63 ± 0.55 14.914 
Patient D 36.76 ± 1.87 37.98  27.70 ± 0.95 29.17  25.15 ± 0.78 26.67  18.72 ± 0.55 20.38  13.85 ± 0.48 14.766 
Patient E 35.01 ± 1.19 35.68  26.01 ± 0.61 26.46  23.38 ± 0.57 23.76  17.28 ± 0.61 17.69  12.94 ± 0.43 13.179 
Patient F 37.71 ± 4.43 38.88  27.96 ± 3.36 30.83  22.80 ± 2.49 24.79  17.29 ± 1.80 18.49  13.51 ± 1.41 14.491 
Patient G 47.56 ± 3.75 48.06  38.10 ± 2.32 38.00  31.16 ± 2.23 29.89  15.55 ± 2.42 14.53  14.94 ± 1.05 14.826 
Patient H 35.62 ± 2.92 38.14  27.09 ± 1.90 28.37  24.52 ± 1.65 25.43  19.50 ± 1.08 20.29  14.22 ± 0.85 15.012 
Patient I 34.09 ± 1.54 35.10  25.63 ± 0.97 26.16  21.15 ± 0.81 21.66  11.21 ± 0.81 11.23  11.72 ± 0.45 11.985 
Patient J 32.18 ± 2.4 31.57  27.69 ± 2.03 27.35  24.45 ± 1.85 24.19  15.87 ± 1.48 15.38  11.79 ± 0.79 11.49 
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2.4 Discussion 
 Multiple studies on tumour volume segmentation uncertainty and variability have 
been performed previously.  Studies performed in the context of both 3D and 4D-CT 
have reported on the effects of target volume segmentation for lung tumours with results 
demonstrating different ranges of uncertainty and/or variability.  The most commonly 
studied influences on segmentation-related geometric uncertainties were the effects of 
inter-/intra-observer variability [54] [55], the relationship between patients breathing 
patterns and image artifact presence [56] [57] [58], and tumour artifacts inherent to the 
4D-CT acquisition modality and/or reconstruction technique [59] [60].  While numerous 
suggestions have been made in efforts to identify, mitigate and/or rectify uncertainty in 
the presence of these sources of error, very little information exists regarding the 
dosimetric and/or radiobiological impact of tumour volume segmentation-related 
geometric uncertainty. Studies by Spoelstra et al. and Le Maitre et al. analyzed the effects 
of tumour volume delineation on subsequent radiotherapy treatment planning for lung 
cancer [61] [62].  Spoelstra et al. demonstrated significant inter-clinician variability in 
lung tumour delineation leading to confounding variability in clinical outcomes and 
emphasized a need for standardization of target volume segmentation.  Their work lead to 
the belief that uncertainty in anatomical delineation was the largest source of systematic 
errors in image guided lung cancer radiotherapy.  This idea has since been extrapolated 
upon and further reinforced by Jameson et al. who made similar conclusions in their 
review of segmentation analysis strategies in radiation oncology [41].  Le Maitre et al. 
examined the dosimetric effect of PET-based functional volume auto-segmentation 
variability and demonstrated a reduction in dosimetric errors using more advanced 
segmentation strategies [62].  However, this study focused on functional volume derived 
from static PET-CT images and lacked the influence of respiratory motion on target 
volume segmentation, which does not reflect current clinical practice.  Thus, our study is 
unique in that we are the first to report on the effects of GTV/IGTV segmentation 
accuracy and variability on IMRT treatment planning for lung tumours in the context of 
4D-CT imaging and respiratory motion.  The results of this study suggest that a wide 
range of variability within 4D-CT derived tumour volume segmentations extends into the 
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treatment planning stages of IMRT and affects both physical and radiobiological 
characteristics of the calculated dose distributions.  The largest variability resulted from 
comparison of primary and nodal target volume dose distributions as well as inter-patient 
comparison.  The dosimetric uncertainty that arises due to variable primary and nodal 
GTV segmentations is most likely attributed the vastly different geometry between these 
structures.  Nodal targets are routinely smaller than primary target volumes and 
accordingly, geometric differences of the same magnitude have different relative effects 
on both segmentation accuracy and dosimetric variability.  Nodal volumes can be quite 
difficult to identify within 3D image volumes without contrast enhancement as they 
typically reside in areas of low contrast and defining normal vs. abnormal lymph nodes 
can be a challenge.  This issue is challenging to address in the context of segmentation 
variability, as it is subject to increased inter-/intra-observer variance as well as image-
induced variability. 
 Previous studies have indicated that PET-CT could be valuable in helping to more 
accurately identify abnormal nodes in lung cancer patients [10] [11] [62] [63] [64] [65] 
[66]. Subsequently, advanced imaging strategies incorporating functional information 
such as PET-CT could possibly incur advantages in reducing dosimetric variability at the 
treatment planning stage for nodal target volumes.  Inter-patient comparison, or patient-
to-patient dosimetric uncertainty fluctuation is considerably more difficult to mitigate. 
Lung tumour geometry is inherently patient specific and highly variable factors such as 
tumour location and disease staging contribute to varying levels of segmentation 
difficulty and variable CT extent for each incoming case viewed by physicians in clinic.  
For the purposes of this study, a wide range of patients was selected to quantify the 
dosimetric impact of target volume segmentation accuracy and variability on treatment 
planning for lung cancer patients.  However, this presents as a limitation in this study.  
Upon further analysis, a correlation between dosimetric variability and patient-specific 
characteristics such as tumour volume, location, and segmentation difficulty as scored by 
observers was found.  Therefore, further sub-classification based on patient-specific 
characteristics prior to analysis would be beneficial for future studies focused on 
quantifying segmentation-related variability in the treatment planning context.  Another 
limitation in this study is the small number of patients and observers.  While only ten 
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patients and six observers were utilized, this provided for approximately six hundred 
manually defined primary and nodal GTV segmentations, yielding a considerable amount 
of data for this and future studies.  It is important to note that considerably more 
information can be acquired and studied in the context of 4D-CT compared to other 
conventional image acquisition techniques with a relatively low number of patients and 
observers when needed.  Such observations may prove valuable in future work with sub-
classified groups where limited patient data is available. 
 A great deal of work is currently being done to address and mitigate geometric 
uncertainties that arise from target volume segmentation.  One of the most common 
solutions presented for this problem is automatic and/or semi-automatic segmentation.  
These strategies rely on the notion that by reducing the amount of manual target volume 
segmentation, inter- and intra-observer variance can be greatly reduced and the 
consistency and integrity of segmentation is increased without sacrificing accuracy 
through an automated framework. However, auto-segmentation strategies pose 
considerable difficulty in both development and implementation.  Segmentation must be 
at least as accurate as manual strategies while also being computationally efficient.  In 
cases where auto-segmentation is used for IGRT, automatic techniques must also be 
validated and incorporated into the routine clinical framework.  Many automated 
segmentation techniques have been proposed, each utilizing different approaches [71] 
[72] [73] [74] [75].  These techniques generally provide a starting point for target 
delineation in the clinical setting, subject to review and edit by physicians.  Atlas-based 
segmentation, while promising for segmentation of structures where the shape is known 
[72], provides little help in lung tumour segmentation. This is because lung tumour 
and/or nodule auto-segmentation require some degree of prior information due to the 
patient-specific nature of tumour geometry and disease characteristics [73].  Thus, atlases 
and statistical models are generally incapable of providing prior information for lung 
tumours due to their patient-specific nature, necessitating manual segmentation to 
provide a geometrical prior. Subsequently, auto-segmentation techniques utilizing 
observer generated geometrical priors fail to fully address the issue of inter-observer 
variability and are somewhat limited in their usefulness for lung tumours.  The possibility 
of amalgamating ground-truth estimation techniques such as thresholded-probability 
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maps [74] or STAPLE [32] based on multiple manual observer segmentations with auto-
segmentation techniques utilizing a prioi information could possibly address this issue. 
However, it would require an exceptionally complex clinical segmentation framework for 
efficient utilization.  Another possible solution to address this problem could be the 
initiation of multi-institution, multi-observer studies focused on determining clinical 
margins to compensate for uncertainties based on target volume definition.  Much like the 
margins that exist to account for microscopic disease, inter-fraction motion and/or setup 
error, clinical margins could be developed to account for geometric uncertainties arising 
in the process of target volume segmentation such as inter-/intra-observer variability 
amongst observers.  This option could be more readily included in clinical practice 
without the need for more complex technological tools.  However, it would also 
necessitate large-scale segmentation studies consisting of multiple observers across 
multiple institutions as well as extensive validation to be fully accepted at the clinical 
level.  Additionally, the inclusion of supplementary information such as that provided by 
hybrid and/or functional imaging would require different sets of guidelines depending on 
the diagnostic information that is available and the disease pathology.  While there is no 
immediate solution to this problem, there are a number of different tools and research 
possibilities to address it as diagnostic imaging and radiotherapy techniques evolve.     
 In the context of image segmentation, this study reported very little difference 
between respiratory-gated and non-gated IMRT treatment planning in terms of target 
volume segmentation uncertainty, target volume coverage and sparing of healthy lung.  
No statistically significant differences between the two treatment methods were 
quantitatively shown.  However, this may be a misleading observation.  Although inter-
observer variability varied on an inter-patient basis, it was consistently quite large in 
analysis of both segmentation and dosimetric variability.  In comparing gated and non-
gated scenarios, this variability appears to be large enough to blur possible distinctions 
between the two treatment methods.  A brief qualitative analysis of figures 2-6 shows the 
amount of variability to be large enough that the difference between gated and non-gated 
segmentations and subsequent treatment plans could be masked.  This can also be 
observed in Table 3 and Table 4, where large variability associated with observer 
segmentation derived treatment plans is large enough to distort distinctions between 
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gated and non-gated plans in terms of dose to healthy lung.  Thus, based on these results, 
the authors contend that the presence of inter-observer variability acts as a confounding 
factor in assessing the potential differences between respiratory gated and non-gated 
IMRT for lung tumours as opposed to there being no significant differences between the 
two methods.  This observation would in part support previous studies in which the 
contention is made that target-volume segmentation uncertainty including inter- and 
intra-observer variability is the largest source of systematic error in the radiotherapy 
process [41] [75] [76].  Additionally, this study neither proves nor disproves any 
previously held notions on the advantages and/or efficacy of respiratory-gated 
radiotherapy that have been previously reported [77] [78].  Both treatment scenarios were 
assessed in this study due to their prevalent use in clinical practice.  However, this may 
have limited the effectiveness of the study by introducing a greater deal of ambiguity to 
the results.   
 For future work in assessing the dosimetric impact of respiratory-gated treatment 
planning, consistent target volume segmentations with little variability should be used to 
avoid confounding factors due to other sources of uncertainty.  Multiple sources of 
uncertainty exist at different stages of the radiotherapy process.  In analyzing these 
sources of uncertainty, one must mitigate variability due to all other factors outside of 
those being analyzed to ensure accurate analysis and to avoid confounding factors as best 
as possible.  While it is important to analyze segmentation variability in the context of 
different image acquisition and reconstruction techniques as well as radiation delivery 
strategies, diligence must be had in assessing said variability and the relationships 
between different sources of uncertainty to ensure both appropriate and effective 
recommendations can be made to improve image guided radiotherapy treatment accuracy 
and efficacy. 
 
2.5  Conclusions 
 A considerable amount of variability currently exists in target volume 
segmentation for lung tumours in the context of 4D-CT imaging.  Based on primary and 
88 
 
nodal lung tumour target segmentations amongst multiple experts in the presence of a 
reference standard, this variability extends into the treatment planning stages for IMRT in 
both respiratory-gated and non-gated scenarios.  Segmentation accuracy was assessed in 
terms of VOE and symmetric RMSD.  Both metrics demonstrated similar trends in 
quantifying segmentation variability amongst experts for lung tumours in 4D-CT 
imaging.  Dosimetric analysis utilizing HI, UI, D95, TCP and NTCP demonstrated that 
this variability was prevalent in subsequent IMRT treatment planning.  Variability was 
typically more severe for nodal target volumes compared to primary target volumes.  
Although the use of 4D-CT allows for more accurate target volume segmentation by 
accounting for respiratory motion, further improvements need to be made to provide for 
more consistent target volume segmentation.  More advanced segmentation strategies 
and/or multi-institutional, multi-expert studies to establish clinical margin guidelines are 
needed to further mitigate the impact of target volume segmentation variability on 
treatment planning for 4D-CT based non-small cell lung cancer radiotherapy.  This is 
especially important as additional sources of uncertainty arise and are possibly magnified 
through the evolution of radiotherapy techniques via accelerated deliveries, increased 
beam modulation, and dose fraction escalation. 
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Chapter 3  
3 Consensus-based lung tumour volume auto-
segmentation in four-dimensional computed 
tomography imaging 
3.1 Introduction 
 In recent years, high-dose image-guided radiotherapy (IGRT) and intensity 
modulated radiation therapy (IMRT) with radical intent has emerged as a treatment 
option for eligible patients.  These processes require the delineation or segmentation of 
tumour volume (the gross tumour volume or GTV) within 3 or 4 dimensional computed 
tomography (CT) images by the physician for treatment plan optimization purposes.  
Subsequent margins are added for clinical target volumes and planning target volumes 
(CTV and PTV, respectively) accounting for uncertainties such as microscopic disease 
and setup error.  Highly accurate segmentation of the GTV is of the utmost importance in 
order to maximize the therapeutic ratio. More advanced treatment planning algorithms 
and radiation delivery techniques further work to enhance radiotherapy precision and 
patient outcomes.  However, as precision improves and prescription dose increases, 
segmentation error and variability in target volume definition can have greater impact on 
treatment efficacy.  Segmentation-related errors including inter- and intra-observer 
variability has been demonstrated with respect to lung cancer in 3D image acquisition [1] 
[2].  While clinical margins exist to account for internal motion of the tumour volume, 
setup error, geographic miss of the target volume and irradiation of healthy tissue, if 
variability and segmentation-related error exceeds the clinical margins, patient outcomes 
and treatment efficacy can potentially be compromised.  Jameson et al. stated that 
variability in anatomical segmentation is the largest contributor to uncertainty in the 
radiotherapy process [3].  This uncertainty can also magnify other sources of error such 
as setup, inter- and intra-fractional motion.  Techniques such as co-registration with 
functional and/or metabolic imaging [4] [5] and automatic segmentation strategies [6] 
have been reported to both reduce segmentation variability due to inter- and intra-
observer variance and expedite the process of image segmentation while maintaining 
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high levels of accuracy.  Caldwell et al. [4] stated “advantages in 3D conformal 
radiotherapy could be offset by variability in GTV segmentation amongst physicians”.  
They subsequently showed that co-registration with FDG PET-CT significantly reduced 
variability in GTV segmentation accuracy.   Steenbakkers et al. [5] also concluded that 
segmentation-related geometric uncertainty was too large for high-precision lung cancer 
radiotherapy.  While espousing the benefits of FDG PET-CT, they noted that further 
improvements needed to be made in mitigating the geometric uncertainties pertaining to 
lung tumour volume segmentation.   
 Further improvements in mitigating segmentation-based geometric uncertainties 
can be made possible by way of automatic segmentation techniques.  Many techniques 
currently exist to segment lung tumours in 3D image datasets that range from 
thresholding techniques utilizing functional and/or metabolic information to dynamic 
programming models with incorporation of different models to assist in segmentation 
accuracy [7] [8] [9] [10] [11].  However, the principle issue in segmentation of lung 
tumours in 3D-CT is the inability of the image acquisition and reconstruction process to 
account for the motion of a moving tumour due to respiratory motion.  Assessing the 
motion of lung tumours is essential for accurate radiotherapy treatment planning and 
delivery purposes.  Movement of tumours during respiration results in different types of 
image artifacts, which have been documented in past studies [12] [13] [14] [15] [16] [17] 
[18].  These artifacts subsequently influence manual, automatic, and/or assisted 
segmentation of the tumour volume.  The addition of arbitrary margins to the segmented 
GTV defined on the artifact inclusive CT scan can subsequently lead to geographic miss 
of the target volume and irradiation of normal, healthy tissue during radiotherapy 
treatment delivery.   
 Many image acquisition techniques are capable of accounting for respiratory 
motion.  Low-pitch, slow-rotating helical CT and breath-hold CT scanning are two of the 
most common approaches to respiratory motion management.  While heavily established 
in the literature, these techniques do have drawbacks.  Breath-hold CT is difficult in 
patients with compromised lung function and ignores the fact that the patient will be 
treated while free breathing with a motion extent principally ignored during image 
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acquisition.  Subsequent tumour volume segmentation on these images will largely ignore 
hysteresis.   In slow CT scanning, a loss of spatial resolution is experienced at the tumour 
boundaries due to motion blurring.  Subsequently, significant observer variance is noticed 
in tumour segmentation [19] [20] [21] [22] [23].  Four-dimensional computed 
tomography (4D-CT) has become the optimal strategy for acquiring artifact-free image 
data and assessing respiratory-induced lung tumour motion.  Numerous studies have led 
to improvements in 4D-CT acquisition reconstruction techniques [24] [25] [26] [27].  4D-
CT image reconstruction allows for free breathing patient CT images to be 
retrospectively sorted into 8-12 respiratory phase-based bins.  These phase-binned image 
datasets are then used for target volume segmentation during different phases of the 
breathing cycle.  Respiratory motion is most commonly tracked via an external surrogate 
such as the Real-Time Position Management (RPM) system (Varian Medical Systems, 
Palo Alto, USA).  This external surrogate records both the amplitude and phase of the 
respiratory cycle in conjunction with image data acquired during corresponding 
amplitudes and phases providing for a 4D-CT dataset used to define a phase-specific 
GTV and an envelope of the GTV throughout a respiratory cycle called the internal gross 
tumour volume (IGTV).  A smaller subset of the IGTV envelope or a GTV from a single 
respiratory phase can also be used for respiratory-gated treatment planning and delivery 
strategies.  While 4D-CT provides an improvement over conventional CT in terms of 
image integrity, defining the IGTV may cause a greater deal of segmentation error and 
geometric uncertainty due to multiple 3D image volumes comprising the entire 4D 
dataset.  A straightforward approach to IGTV segmentation is to have experts segment 
the GTV on each individual respiratory phase and then integrate those segmentations.  
However, time requirements and considerable amounts of inter- and intra-observer 
variability limit the clinical feasibility of this practice.  Many studies have reported on 
IGTV segmentation in 4D-CT datasets [28] [29] [30].  Reports on the effectiveness of 
maximum- and average-intensity projection CT images offer marginal improvement and 
mixed results in the context of plan dosimetry [31] [32].  End exhalation and end 
inhalation phases of the 4D-CT dataset have also been used for target volume 
segmentation but these strategies do not account hysteresis during intra-fraction motion 
and misses motion outside of the boundary defined by the two phases.   
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Auto-segmentation strategies have the potential to simultaneously reduce 
segmentation time and mitigate segmentation-related geometric uncertainties in 4D-CT 
and strategies utilizing deformable surface models and/or deformable image registration 
techniques have been reported with varying levels of success [33] [34] [35] [36] [37] [38] 
[39] [40].  It is vital that auto-segmentation strategies in 4D-CT are both efficient and 
highly accurate to limit the need for physician editing.  While auto-segmentation 
reduces the clinical workload and the potential for intra-physician variance, inter-
physician variance remains a problem.  Additionally, when quantitatively evaluating 
image segmentation, numerous questions arise in the context of multi-expert studies and 
assessing automatic segmentation performance.  These questions were summarized 
concisely by Gordon et al..  Ground-truth (GT) estimation algorithms aim to address 
those questions by incorporating multiple expert markings and providing for a reference 
standard segmentation in quantitative evaluation and validation of medical image 
segmentation analysis [41] [43].  The ability to incorporate multiple expert image 
marking allows for generation of estimates of lesion locations that take into account 
multiple physicians' input with an expectation that a result is a closer representation to the 
tumour’s true location due to the assumed minimization of each expert's subjectivity in 
segmentation [41] [42]..  Biancardi and Jirapatnakul summarized multiple GT algorithms, 
comparing threshold probability maps, truth estimates from self distances (TESD), and 
the simultaneous truth and performance level estimation algorithm (STAPLE) in an effort 
to find which technique most accurately estimates the GT tumour location [42].  Their 
work demonstrated a superiority of the STAPLE algorithm in establishing GT estimate 
segmentations for lung nodules.   
 The goal of this paper is to couple consensus-based tumour volume segmentation 
in 4D-CT datasets based on N physicians input segmentations with a deformable model 
based automatic segmentation technique for multi-expert 4D-CT tumour volume auto-
segmentation.  Each 4D image sequence is manually segmented allowing for each 3D 
image volume within the 4D dataset to have a reference, STAPLE derived segmentation.  
Those segmentations are subsequently used as the basis for auto-segmentation to the 
other respiratory phase specific 3D image volumes, which are then analyzed via 
comparison to the manually derived STAPLE segmentations.  Through this process, we 
 can both determine the efficacy and accuracy of auto
approximately which state of the breathing cycle (e.g. maximum exhalation, 
inhalation, maximum inhalation, mid
tumour volume auto-segmentation in the context of 4D imaging.
Figure 3-1: Representative slices in the axial, 
6 physicians manual GTV segmentation on all 10 respiratory phases for patients B, E, F, 
and H, in panels (i) through (iv), respectively.
-segmentation as well as determine 
-exhalation, etc.) provides the optimal basis for 
 
sagittal, and coronal planes and 3D view of 
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3.2 Methods and Materials 
3.2.1 Image Acquisition and Reconstruction 
 4D-CT imaging was performed on ten patients with NSCLC. Patient 
demographics and disease information are presented in Table 1.  Local REB approval 
was obtained and all data was anonymized prior to any segmentation.  A Philips 16-slice 
Brilliance Big Bore CT scanner (Philips Medical Systems, Cleveland, USA) was used 
with the pulmonary gating application to image patients.  The Real-Time Position 
Management (RPM) respiratory gating system (Varian Medical Systems, Palo Alto, 
USA) was used as a respiratory surrogate.  The RPM system uses an infrared camera that 
follows reflective markers placed on the patient's chest or abdomen.  For all ten patients, 
a long spiral CT scan with pitch < 0.1 was performed to encompass the entire thorax.  
Pulmonary signal data was collected from the RPM system simultaneously with CT data.  
CT data was then reconstructed at ten different respiratory phases (i).  Respiratory phases 
were tagged according to temporal location along the respiratory cycle, indicating 
temporal steps from one full inspiration phase to another (i = 0, 10, ..., 90%).  This form 
of image reconstruction allows for visualization of tumour volume displacement at ten 
equally spaced points in time throughout the respiratory cycle.  Due to this 4D 
reconstruction method, for all patients the phases (i) correspond to each other. 
Table 3-1: Patient demographic, disease information, and manual segmentation difficulty 
Patient Staging MSD* Location Volume (cm3) 
A IIIA 3.00 (Difficult) RLL 272.63 
B IIIA 4.50 (Difficult) RLL 67.70 
C IIB 3.00 (Difficult) RLL 29.86 
D IIIA 1.83 (Easy) RLL 46.99 
E IIIA 1.33 (Easy) LLL 10.42 
F IIB 3.50 (Difficult) RUL 17.95 
G IIIA 2.17 (Easy) LUL 2.24 
H IIIA 3.33 (Difficult) LUL 20.80 
I IIB 1.83 (Easy) RLL 28.18 
J IIIA 2.50 (Easy) RUL 90.10 
*MSD: Mean Segmentation Difficulty    
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3.2.2 Manual Segmentation 
 The GTV was segmented on each of the ten respiratory phases for ten patients by 
six radiation oncologists with clinical experience ranging from 1 to 25 years experience.  
Target volume segmentation was done within the Pinnacle Treatment Planning System 
(Pinnacle; Milpitas, USA) and patient image data was anonymized to avoid possible 
identification of original subjects.  Default visualization parameters were used for lung 
tumour segmentation by all physicians in accordance with recommendations by Giraud et 
al. [1] (-600/1600 HU for lung window, +20/400 HU for the mediastinal window) and a 
variable zoom factor was applied to all images prior to manual segmentation.  The IGTV 
envelope, defined as the union of GTV segmentation from all respiratory phases was 
created using MiMVista v.5.2 (MiM Software, Cleveland, USA).  Experts were blinded 
to one another's segmentations and were provided with a representative axial 2D CT 
image indicating location of the primary GTV.  Upon completion of manual 
segmentation, experts were asked to assign a difficulty level on a scale of 1 (least 
difficult) to 5 (most difficult) for each case.  The five cases with average difficulty above 
2.5 were classified as difficult while the remaining cases were classified as easy.  Patient 
characteristics and manual segmentation difficulty scores can be seen blow in Table 3-1. 
3.2.3 Consensus Segmentation 
 Quantitative analyses of lung tumours involving manual and/or automatic 
segmentations have shown results that were historically difficult to evaluate.  This is due 
to measures of segmentation accuracy typically being based on comparison between 
segmentation and ground truth, which is typically defined by a single expert observer.  As 
such, intra- and inter-observer variances are inherent and strategies involving multiple 
expert segmentations should be incorporated to provide more informed segmentations 
and to avoid observer variance.  While several approaches to defining a ground truth have 
been proposed, the STAPLE algorithm has been shown to be both highly robust and 
adept at incorporating and fusing multiple expert segmentations into one GT estimate 
segmentation or multi-expert GT segmentation [42].  The STAPLE technique, proposed 
by Warfield et al. [45], takes a collection of J binary image segmentations as inputs and 
simultaneously computes a probabilistic estimate of the true tumour segmentation and a 
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measure of the performance level of each observer's input segmentation.  Segmentation 
information is available as decision dij, indicating the label given by each expert j for 
each voxel i.  The goal of STAPLE is then to estimate the ground truth (GT), or reference 
standard segmentation T, and the parameters that describe the agreement between experts 
and the GT estimate given by   , … ,  , … , .  Each parameter   is a    
matrix, where N is the number of labels in the segmentation, and ′ is the probability 
that expert j gave the label s' in the voxel i when the reference standard label is given by 
s, for example: ′    ′  .   
The algorithm utilizes an expectation-maximization approach to improve the 
initial GT estimate in an iterative fashion.  In the E-step, the unobserved true 
segmentation is computed as a probability map where each voxel is assigned a 
probability of being a part of the segmented object (tumour volume).  The E-step of the 
EM algorithm aims to compute the unobserved true segmentation.  This involves 
estimating the conditional expectation of the complete data log likelihood function given 
by |!" (where k is the iteration number) knowing the expert parameters at each 
previous iteration: !. This requires the knowledge of the posterior probability of : |$, !", which then allows for the maximization step.  In the M-step, observer's 
performance level parameters are estimated at iteration % & 1, given by !(" by 
maximizing the complete data log-likelihood using the current reference segmentation 
generated at the E-step.  Performance parameters are based on sensitivity and specificity 
estimators, which correspond to the degree to which voxels are correctly predicted to be 
or not to be a part of the GT, respectively.  Initial values for sensitivity and specificity 
can be given in some cases or they can be approximated by comparing individual 
segmentations to a segmentation comprised of all observer segmentations with a majority 
vote.  In this study, all observers were assigned the same initial sensitivity and specificity 
as their true explicit segmentation quality is unknown, as per suggestions made by 
Warfield et al.  The final step of the STAPLE algorithm is the generation of the final 
estimate of GT based on the construction of a hidden Markov Random Field (MRF).  In 
this step, the relationships between voxels and their neighbors are used to regularize the 
EM estimate and the finding of the optimal solution or final estimate is a max-flow min-
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cut problem with a modified implementation of the work by Boykov and Kolmogorov 
[42] [45] [46] [47].  In using the STAPLE algorithm for GT estimation, it is important to 
remember that the algorithm itself benefits from prior information made available by way 
of input segmentation reliability.  This means that the performance of the GT estimate 
relies on the level of expertise of the observers who’s input segmentation are used to 
formulate the GT estimate.  As such, radiation oncologists from the London Regional 
Cancer Program (LRCP) were selected to provide input manual segmentations for this 
study. 
 
Figure 3-2: Example result of STAPLE-based probabilistic estimate of the true 
segmentation from multiple expert input segmentations in the axial, sagittal, and coronal 
image planes.  Top Panels represent multiple physicians’ manual tumour volume 
segmentations.  Bottom panels represent STAPLE algorithm GT estimate segmentation. 
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3.2.4 Auto-segmentation 
 Deformable surface models have been used previously in the setting of respiratory 
motion and 4D-CT imaging, demonstrating robustness with respect to image artifacts and 
consistent capturing of deformation at all respiratory phases.  The demons deformable 
registration algorithm, a technique utilizing deformable surface models originally 
proposed by Thirion [48], was chosen to provide the basis for the auto-segmentation used 
in this study.  This method utilizes an instantaneous optical flow concept to determine the 
forces that deform a moving image to a fixed image by pushing iso-intensity contours in 
the normal direction.  The demons algorithm utilizes an iterative approach starting with 
an initial deformation field.  This field is iteratively updated in steps, beginning with 
deformation first determined at a coarse level that initializes registration at a finer scale 
that is iteratively repeated until it reaches the finest possible scale.  Enhanced versions of 
the demons algorithm have been proposed utilizing iteration step width control [49] and 
symmetric forces [38].  However, a diffeomorphic algorithm was used as the registration 
model for auto-segmentation purposes in this study [50].  In addition to prior applications 
of thoracic imaging influenced by respiratory motion [51] [52], the advantage of such an 
approach is that by combining a Lie group framework on diffeomorphisms with an 
optimization technique for Lie groups, the demons algorithm is adapted to ensure 
diffeomorphic dense field transformation more analogous to the true deformation of the 
image object [53] [54].  This registration technique is explained fully in [51] and [38].  
Auto-segmentation is made possible by initial non-parametric image registration.  In 
general, given two images f and m, image registration is treated as an optimization 
problem aimed at finding the displacement between image pixels to achieve a reasonable 
alignment of the images, given as:    
+r, "  1s? t\u, \°" & 1sH? t[, r"? & w9x", (1) 
where m◦s represents the moving image, m, under the transformation s, establishing 
correspondences between image pixels (vector field given by c)  and Sim(f, m◦s) is the 
similarity criterion measuring the similarity between the two registered images that drives 
the mesh towards detected surface points.  The Reg(s) regularizes the dense field 
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transformation, which allows for the perseveration of the vertex configuration of the 
initial mesh.  The s factor accounts for noise on the image intensity and the alpha factor 
controls the amount of regularization.  The sH factor accounts for spatial uncertainty in 
correspondences and t[, r"  yr - y.  For registration purposes, the normalized 
cross-correlation (NCC) similarity metric was used to measure the degree of shared 
information between two images. The NCC coefficients between two 2D images is given 
as: 
NNEU , EF  ∑ EUd, {" - EF|||"EFd, {" - EU}"H,~∑ EUd, {" - EF|||?H,~ ∑ EFd, {" - EU}?H,~  , (2) 
where EUd, {" and EFd, {" are the pixel values at pixel x and y of images EU and EF, 
respectively.  EU}  and EF||| are the mean pixel values of images EU and EF, respectively.  The 
NCC coefficient varies between the values of -1.0 and 1.0 where a value of 1.0 
corresponds to a perfect image matching.  After implementing the NCC during 
registration to find the best image alignment, post-registration NCC measurements were 
equal to, or greater than 0.99 for all registrations/auto-segmentations.  NCC is both easy 
to implement and quick to compute and has shown to be reliable in the context of 4D-CT 
dataset registration [55].  The NCC similarity metric is valuable in cases such as this, 
where registration is performed between images acquired from the same modality.  This 
typically negates the need for more robust measures like mutual information (MI), which 
are more useful in multi-modal imaging, fluoroscopy, or angiography [56].  Auto-
segmentation is made possible by a deformable model based method.  Post-registration, a 
triangular surface mesh is adapted to an image through an iterative process of surface 
detection and reconfiguration of triangle vertices through minimization of the energy 
function +  +THb. & w+Ib.".  The internal shape energy term +Ib." maintains the 
vertex configuration of an intial mesh while the w parameter regulates the influence of 
the external feature energy term +THb.". This drives the mesh toward detected surface 
points.  Surface detection is performed for each triangle center and achieved by 
maximizing a cost function that evaluates displacements along the triangle normal to 
deform to a feature based on grey-scale value transitions while simultaneously restricting 
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large displacement vectors [33].  No auto-segmented volumes in this study were subject 
to any form of physicians review to allow for unbiased assessment of the auto-
segmentation accuracy. 
 
3.2.5 Accuracy Validation 
 To assess the accuracy of the proposed consensus-based segmentation strategy in 
this study, reference respiratory phase specific STAPLE GTV segmentations were 
propagated to all other respiratory phases within the 4D-CT dataset for all patients.  
Subsequently, respiratory-phase specific, auto-segmented IGTV segmentations were also 
generated.  These auto-segmented volumes were then compared to their respiratory phase 
respective manually derived, true STAPLE segmentations that were available for all 
respiratory-phase GTV and IGTV segmentations.  In this way, auto-segmented STAPLE 
segmentations for all possible tumour volume segmentations could be compared back to a 
reference, manually derived STAPLE volume to assess accuracy.   
 As stated by Chalana and Kim, well-defined metrics are needed to compare the 
computer-generated or automatic segmentation results to the manual segmentation results 
produced by expert observers. Such metrics are difficult to define and establish consensus 
in the context of image segmentation because of the complex multi-dimensional nature of 
segmentation data [43].  A large number of measures and techniques exist for this 
purpose.  Jameson et al. and van der Put et al. both summarize methods and techniques in 
analysis and comparison of 3D target volume segmentations [3] [57].  Commonly used 
metrics are typically based on volumetric overlap and surface distances with different 
mathematical definitions.  Additionally, descriptive statistics and statistical measures of 
agreement are also of value in segmentation analysis, more so in the context of assessing 
inter- and intra-observer variance [58].  Generally speaking, a combination of 
segmentation analysis metrics should be used as each one highlights a different facet of 
segmentation accuracy and quality.    
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Following the work by Heimann et al., measures were chosen for this study that 
highlighted both average and maximum surface distance errors as well as volumetric 
error to better convey information regarding segmentation quality and estimate overall 
segmentation accuracy [44].  To analyze the segmentation volumes in this study, a global 
optimization framework (e.g. graph-cut) for 3D shape reconstruction was implemented to 
allow for 3D analysis of segmented volumes outside of the treatment planning system 
(TPS) in which the volumes were originally segmented.  The method proposed by 
Lempitsky and Boykov was used for this as it provided for robust, high-resolution surface 
reconstruction with global optimality [59].  This technique was used in conjunction with 
a surface-extraction technique with higher-order smoothness [60] for improved 
visualization and qualitative analysis of the reconstructed segmentation volumes as well.      
3.2.5.1 Volume-based Analysis 
 Volume-based metrics are some of the most commonly used metrics in analysis of 
tumour volume segmentation accuracy and quality.  Numerous studies have implemented 
volume metrics yielding different results and different opinions regarding the 
effectiveness of said metrics and are summarized in studies by Fotina et al and Jameson 
et al. [58] [3].  Two of the most common metrics are the Dice Similarity Coefficient 
(DSC) and the Jaccard Index (JI).  These metrics have both been used extensively in 
segmentation analysis and are closely associated mathematically, with little preference 
shown for one or the other. However, a recent study by Fotina et al. demonstrated that the 
DSC allots double value to the overlap area and tends to over-estimate the amount of 
agreement between two segmentations [58].  As such, the JI was chosen as the volumetric 
overlap metric in this study.  The volumetric overlap (VO) is then given as a percent of 
agreement between two volumes and is defined as 100%  	C0@C2@
.  This ratio between 
the intersection and union of two segmented volumes is also known as Tanimoto 
coefficient [61].  A value of 0 represents complete disagreement between volumes, while 
a value of 100% represent perfect volumetric overlap.  The VO calculations were made 
possible by way of the globally optimal surface reconstruction technique utilized in this 
study.  
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3.2.5.2 Distance-based Analysis 
 Distance-based metrics typically involve development of methods to calculate 
differences in segmentations based on shape and/or surface comparisons between two 
segmentations.  Many methods for calculating distance-based evaluation metrics for 
segmentation analysis currently exist and are summarized by Jameson et al. [3].  
Typically, these methods of analysis rely on software developed either in-house or from a 
third party to calculate the desired metrics.  For this study, the root mean square (RMS) 
symmetric surface distance and the maximum symmetric surface distance (or Hausdorff 
Distance) (HD) measures were calculated as they represent the average and maximum 
errors measures between segmentations.  The RMS symmetric surface distance is 
measured in millimeters (mm) and is based on surface voxels of two separate 
segmentations, whose surfaces are given by S(A) and S(B), and point clouds representing 
segmentations given by A and B, respectively.  As each segmentation is a 3D point cloud, 
the coherent point drift (CPD) algorithm [62] was used to calculate distance-based 
metrics in this study.  This registration technique was chosen to provide for symmetric 
correspondence in measurement between point clouds.  Typically, in calculating the RMS 
distance between two point clouds, say the distance from each point a in cloud A to its 
corresponding point b in B, the metric will be weighted largely by non-overlapping parts 
and registration and measurement of distance between the two will be asymmetric.  To 
overcome this and establish symmetric correspondence, we adopt a methodology for 
calculating the RMS symmetric surface distance by first implementing CPD, then 
utilizing an approximate nearest neighbor technique.  Using CPD, we register A to B, 
yielding A' and finding the nearest neighbor correspondence of each point in A' in B to 
yield B-neighbors, a new unique set.  We then register B-neighbors to A, yielding B-
neighbors' and calculate the approximate nearest neighbors of each point of B-neighbors' 
in A.  This yields the unique set A-neighbors.  Using the two point clouds, A-neighbors 
and B-neighbors, we can calculate the RMS distance between the two with symmetric 
correspondence.  This is done by calculating and storing the squared Euclidean distance 
between each set of corresponding points.  The average RMS symmetric distance is then 
defined as the average of all stored distances, where 0 represents a perfect segmentation.  
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Formally, the distances between corresponding points in S(A-neighbors) and S(B-
neighbors) is given by:   
 	/ , 7I"
 ,  	1 , 8I"
 
The symmetric RMS distance is then given by:  
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(3) 
The RMS symmetric distance highly correlates with the average distance.  However, by 
squaring the distances between points, larger deviations between surfaces are punished 
stronger.  As stated by Heimann et al., this metric is one of the most important in 
evaluating segmentation accuracy [44].  The maximum symmetric surface distance 
(MSD) is also measured in millimeters and is determined implicitly with the RMS 
symmetric distance.  This measure is better known as the Hausdorff distance (HD) [63] 
and is determined as the maximum Euclidean distance or maximum symmetric surface 
distance.  A perfect match between two segmentations yields a value of zero, and this 
measure is formally given as:  
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This metric was included as it gives the maximum error in segmentation analysis with 
sensitivity to outliers.   To determine the statistical significance of the measures used in 
this study, two analysis methods were used.  To determine statistical significance 
between GTV and IGTV measurements (between-groups), post-hoc, unequal variance t-
tests were used (Welch's t-test).  This allowed for comparison of unequal populations 
(GTV and IGTV measurements) for each patient. In determining the statistical 
differences between respiratory phase-specific measurements (within groups), a one-way 
ANOVA test was used.  This test allowed us to determine statistical differences between 
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respiratory phase-based GTV measurements on an intra-patient basis.  For both tests, p-
values<0.05 were considered statistically significant.  
 
3.3 Results 
 A summary of volumetric overlap for respiratory phase-based GTV and IGTV 
auto-segmentation for all ten patients is shown in Table 3-2.  GTV auto-segmentation 
was subject to varying accuracy across the patient group ranging with respect to 
volumetric overlap, ranging from (81.51 ± 1.92)% to (97.27 ± 0.28)% agreement, and a 
median value of 92.16% across all phases and patients.  IGTV auto-segmentation 
demonstrated significantly improved accuracies with reduced variance for all ten patients 
ranging from 90.87% to 98.57% volumetric overlap and a median value of 95.68% across 
all phases and patients.  Histograms of GTV and IGTV overlap measurements are shown 
in Figure 3-3.  Overall, these measures demonstrate consistency in the relative location 
accuracy of auto-segmented GTV and IGTV structures.  Symmetric RMS surface 
distances are summarized in Table 3-3.  These distance-based measurements 
demonstrated a similar trend to volumetric overlap measurements with reduced error for 
IGTV segmentations.  GTV surface-to-surface deviations ranged from (3.18 ± 0.05)mm 
to (4.73 ± 0.05)mm and a median value of 3.64 mm in surface-to-surface distance for 
respiratory phase-specific GTV segmentations across all phases and patients.  IGTV 
measurements showed a reduced range of value with smaller variance, ranging from 
2.68mm to 4.21 mm, with a median value of 3.10mm across all phases and patients.  
Histograms of GTV and IGTV surface distances are shown in Figure 3-4.  Statistically 
significant reduction in both surface-to-surface distances and volumetric overlap were 
observed for all patients, suggesting that the GTV envelope or IGTV segmentation 
reduces the uncertainty in 4D-CT based target volume segmentation.   
 For GTV segmentation, 1-way ANOVA demonstrated that the choice of 
respiratory phase for the basis of auto-segmentation provided for statistically significant 
differences in accuracy with respect to both volumetric overlap and RMS distance 
measures. Currently, no clinical interpretation of volumetric overlap indices exists 
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making the metric difficult to analyze in the context of treatment efficacy and patient 
outcomes.  However, Table 3-2 shows that the difference in average volumetric overlap ∆" between phases was <5% for all patients except patient C.  Therefore, while 
statistically different, these differences are quite small and are not indicative of optimality 
for any specific respiratory phase as a basis for auto-segmentation.  While symmetric 
RMS distances also showed significant differences between respiratory phases, they also 
did not indicate optimality for any specific respiratory phase as a basis for auto-
segmentation.  This is due to the fact that the differences in symmetric RMS measures 
were sub-millimeter and clinical margins in the context of radiotherapy are considered on 
the order of millimeters.  As such, while differences due to the choice of propagation 
phase were statistically significant, they are not clinically relevant.  These two 
observations indicate that the choice of respiratory phase for the basis of auto-
segmentation may be arbitrary, and certain phases such as the end-exhale (50%) or end-
inhale (0%) phases do not provide for better auto-segmentation results than any other 
individual phase when propagating tumour volume segmentation through the entire 4D-
CT dataset.   
 Table 3-4 shows maximum symmetric RMS surface distances (or Hausdorff 
distances) for GTV and IGTV segmentations. Hausdorff distances were quite variable 
across the patient groups and showed no specific trends.  GTV and IGTV segmentations 
showed no statistically different results, and increased Hausdorff distances were observed 
in cases with increased manual segmentation difficulty as graded by physicians.  Based 
upon 3D surface reconstruction, the largest Hausdorff distances were typically due to 
segmentation variability confined to the base and/or apex of the target volume (see Fig. 
3-5).  ANOVA between respiratory phases again showed significant differences in 
segmentation.  However, for this metric, deviations were on the order of millimeters 
meaning they were of clinical relevance.  No particular respiratory phase showed a 
propensity for lower Hausdorff distance calculations, and it's value in this study is 
somewhat limited by the lack of statistical significance or visible trend in the data.  
However, this metric could be of value in a clinical setting by allowing physicians to 
view regions of largest disagreement between two segmentations.  In the context of high 
dose fractionation and/or dose escalation for radiotherapy techniques such as stereotactic 
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ablative radiotherapy (SABR) [64] and radio-surgery [65], error on the scale of 
millimeters and centimetres must be mitigated to ensure healthy tissue and organs at risk 
are spared adequately.  Figures 3-5 and 3-6 show surfaced rendered manually derived 
STAPLE IGTV segmentations with surface meshes of end-exhalation based auto-
segmented IGTV overlaid for easy and difficult cases, respectively.  Qualitative analysis 
shows that the auto-segmentation has a propensity to overestimate target volumes.  
However, the geometry of auto-segmented volumes remains highly consistent with the 
reference STAPLE segmentations demonstrating that deformable model-based 
techniques are capable of robust segmentation in the presence of both simple and 
complex tumour volume geometries under the influence of respiratory motion.  All 
segmented volumes in this study were not subject to any form of physicians review to 
allow for unbiased assessment of the auto-segmentation accuracy.  However, when 
delineating target volumes for radiotherapy treatment plan optimization, time to review 
and edit these volumes must be given to physicians to compensate for any geometric 
uncertainties.   
 
 
 
 
 
 
 
 Figure 3-3: Histograms of volumetric overlap measurements after auto
GTV and IGTV volumetric measurements are shown in (a) and (b), respectively.
 
Figure 3-4: Histograms of 
segmentation.  GTV and IGTV surface measurements are shown in (a) and (b), 
respectively. 
 
symmetric RMS surface distance measurements after auto
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-segmentation.  
 
 
-
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Figure 3-5: CT images depicting STAPLE-based IGTVs (red) (left panels), and surface 
renderings of IGTV auto-segmentation based on the end-inhalation phase (0%)(black 
mesh) and end-exhalation phase (50%) (transparent yellow) (right panels) for more 
variable cases such as patient C (a) and patient H (b). 
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Figure 3-6: CT images depicting STAPLE-based IGTVs (red) (left panels), and surface 
renderings of IGTV auto-segmentation based on the end-inhalation phase (0%)(black 
mesh) and end-exhalation phase (50%) (transparent yellow) (right panels) for less 
variable cases such as patient E (a) and patient I (b). 
 
 
 
  
120 
Table 3-2: Volumetric overlap measurements from each respiratory phase derived auto-segmentation.  Average values are shown for 
GTV structures, single values shown for IGTV structures.    
Propagation 
Phase 
(%) 
 Patient A   Patient B   Patient C   Patient D   Patient E  
 
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%) 
0.0  96.58 ± 0.61 98.10  92.49 ± 0.87 95.40  87.57 ± 1.48 91.45  94.20 ± 0.43 96.43  92.65 ± 1.12 94.80 
10.0  96.50 ± 0.42 97.96  92.34 ± 0.50 95.91  86.90 ± 0.97 92.59  94.12 ± 0.42 96.99  90.19 ± 0.97 94.24 
20.0  97.19 ± 0.30 98.14  93.57 ± 0.78 96.09  86.24 ± 0.71 91.18  93.19 ± 0.35 96.17  91.79 ± 1.28 94.51 
30.0  97.04 ± 0.14 98.10  93.94 ± 0.50 95.89  87.95 ± 0.88 92.78  93.92 ± 0.30 96.75  92.48 ± 1.07 95.49 
40.0  97.07 ± 0.42 97.99  93.17 ± 0.82 95.73  89.19 ± 2.68 91.91  95.16 ± 0.39 97.00  90.23 ± 1.83 95.04 
50.0  95.07 ± 0.67 98.57  92.71 ± 1.20 96.23  89.54 ± 0.86 92.42  93.01 ± 0.52 97.23  90.90 ± 1.38 95.14 
60.0  96.25 ± 0.15 97.88  93.81 ± 0.89 96.07  87.98 ± 1.92 90.87  95.17 ± 0.25 96.45  91.32 ± 1.26 94.32 
70.0  96.90 ± 0.24 97.82  93.06 ± 0.71 96.18  81.51 ± 1.93 92.14  94.83 ± 0.66 96.37  92.48 ± 1.01 94.07 
80.0  97.21 ± 0.28 98.03  92.54 ± 0.82 96.54  86.58 ± 3.03 91.60  93.88 ± 0.68 96.46  90.80 ± 1.72 94.30 
90.0  97.27 ± 0.28 98.26  93.59 ± 0.60 96.05  90.10 ± 1.47 92.01  94.95 ± 0.29 96.96  91.93 ± 1.01 94.46 
p(within 
group)   p<0.0001   p<0.0001   p<0.0001   p<0.0001   p<0.0001 
p(between 
groups)   p<0.0001   p<0.0001   p<0.0001   p<0.0001   p<0.0001 
                
Propagation 
Phase 
(%) 
 Patient F   Patient G   Patient H   Patient I   Patient J  
 
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%)  
GTV ± SD 
(%) ITV (%) 
0.0  89.21 ± 1.15 92.26  88.30 ± 2.06 96.03  89.93 ± 0.62 95.85  92.11 ± 0.75 95.86  96.31 ± 0.40 96.42 
10.0  89.43 ± 1.05 91.41  88.27 ± 2.75 95.22  87.85 ± 0.48 94.94  93.28 ± 1.32 95.94  95.12 ± 0.31 97.07 
20.0  88.71 ± 0.96 93.50  90.10 ± 1.24 93.69  87.89 ± 1.00 94.89  93.57 ± 1.18 96.21  96.46 ± 0.37 96.80 
30.0  87.97 ± 1.10 91.40  89.18 ± 1.55 92.21  89.05 ± 0.68 95.41  92.84 ± 0.71 95.56  95.94 ± 0.27 97.25 
40.0  88.44 ± 1.25 93.29  89.96 ± 1.01 93.58  88.97 ± 0.80 95.34  94.08 ± 0.77 96.28  96.07 ± 0.51 96.58 
50.0  87.25 ± 1.28 91.23  88.99 ± 2.18 95.05  89.57 ± 0.75 95.63  95.36 ± 0.58 95.59  95.27 ± 0.40 96.80 
60.0  88.45 ± 1.24 91.58  89.30 ± 1.37 92.68  89.12 ± 0.67 95.00  91.92 ± 1.08 96.17  95.89 ± 0.34 96.40 
70.0  89.49 ± 2.06 92.84  90.74 ± 0.93 94.96  89.18 ± 0.80 95.76  93.63 ± 0.98 96.33  96.52 ± 0.58 96.92 
80.0  90.74 ± 1.57 92.49  89.87 ± 1.42 94.52  90.58 ± 0.79 94.85  93.91 ± 1.00 95.91  95.52 ± 0.19 96.59 
90.0  88.20 ± 0.98 91.53  89.02 ± 2.96 94.83  89.80 ± 0.71 95.57  91.91 ± 1.50 96.05  96.02 ± 0.66 96.88 
p(within 
group)   p<0.0001   0.1237   p<0.0001   p<0.0001   p<0.0001 
p(between 
groups)   p<0.0001   p<0.0001   p<0.0001   p<0.0001   p<0.0001 
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Table 3-3: Surface distance measurements from each respiratory phase derived auto-segmentation.  Average values are shown for 
GTV structures, single values shown for IGTV structures.    
Propagation 
Phase 
 Patient A   Patient B   Patient C   Patient D   Patient E  
 
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm) 
0.0  3.67 ± 0.12 2.91  4.17 ± 0.17 3.57  4.22 ± 0.26 3.33  3.50 ± 0.10 2.96  3.23 ± 0.17 2.77 
10.0  3.80 ± 0.11 2.86  4.08 ± 0.22 3.49  4.17 ± 0.32 4.21  3.54 ± 0.19 2.94  3.58 ± 0.17 2.85 
20.0  3.75 ± 0.10 3.05  3.98 ± 0.26 3.72  4.73 ± 0.28 4.18  3.62 ± 0.17 2.91  3.31 ± 0.13 2.68 
30.0  3.52 ± 0.08 2.87  3.94 ± 0.26 4.49  4.05 ± 0.27 3.69  3.46 ± 0.07 2.86  3.43 ± 0.23 2.86 
40.0  3.67 ± 0.16 3.11  3.96 ± 0.22 3.95  4.26 ± 0.37 3.06  3.46 ± 0.14 2.82  3.41 ± 0.18 3.00 
50.0  3.65 ± 0.12 2.88  4.17 ± 0.25 3.66  4.32 ± 0.14 3.52  3.71 ± 0.13 3.04  3.38 ± 0.27 2.95 
60.0  3.85 ± 0.17 3.07  4.21 ± 0.24 3.88  4.28 ± 0.40 3.54  3.57 ± 0.21 3.02  3.55 ± 0.34 3.18 
70.0  3.72 ± 0.16 3.05  4.16 ± 0.26 3.71  3.91 ± 0.30 3.61  3.56 ± 0.21 3.29  3.49 ± 0.28 3.19 
80.0  3.87 ± 0.15 3.00  4.08 ± 0.20 3.39  3.95 ± 0.29 3.95  3.33 ± 0.08 2.91  3.39 ± 0.13 2.86 
90.0  3.65 ± 0.14 3.04  4.31 ± 0.23 3.56  3.84 ± 0.35 3.54  3.34 ± 0.14 2.90  3.43 ± 0.26 2.92 
p(within 
group)   p<0.0001   0.015849   p<0.0001   p<0.0001   0.0552 
p(between 
groups)   p<0.0001   p<0.0001   0.0013   p<0.0001   p<0.0001 
                
Propagation 
Phase 
 Patient F   Patient G   Patient H   Patient I   Patient J  
 
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm) 
0.0  3.62 ± 0.13 3.04  3.46 ± 0.57 3.18  3.42 ± 0.08 3.29  3.65 ± 0.23 3.06  3.18 ± 0.05 2.78 
10.0  3.60 ± 0.09 3.52  3.46 ± 0.49 3.09  3.68 ± 0.16 3.07  3.71 ± 0.25 3.45  3.46 ± 0.14 2.80 
20.0  3.92 ± 0.15 3.48  3.65 ± 0.15 3.48  3.74 ± 0.17 3.14  3.45 ± 0.21 3.10  3.52 ± 0.10 2.88 
30.0  3.77 ± 0.12 3.60  3.32 ± 0.47 3.51  3.57 ± 0.10 3.10  3.51 ± 0.21 3.07  3.29 ± 0.08 2.83 
40.0  3.68 ± 0.09 3.21  3.51 ± 0.58 3.07  3.63 ± 0.15 3.16  3.62 ± 0.26 3.16  3.39 ± 0.08 2.71 
50.0  3.64 ± 0.22 3.42  3.63 ± 0.46 3.33  3.49 ± 0.15 3.28  3.38 ± 0.30 3.19  3.35 ± 0.11 2.87 
60.0  3.71 ± 0.13 3.73  3.76 ± 0.49 3.33  3.87 ± 0.22 3.02  3.65 ± 0.31 2.89  3.50 ± 0.15 2.70 
70.0  3.62 ± 0.22 3.58  3.61 ± 0.46 2.97  3.70 ± 0.22 3.02  3.62 ± 0.20 3.09  3.50 ± 0.14 2.85 
80.0  3.60 ± 0.21 3.42  3.61 ± 0.30 3.32  3.61 ± 0.17 3.21  3.45 ± 0.15 3.08  3.40 ± 0.09 2.79 
90.0  3.84 ± 0.17 3.32  3.40 ± 0.45 3.57  3.39 ± 0.09 3.18  3.67 ± 0.22 3.29  3.27 ± 0.10 2.70 
p(within 
group)   0.006992   0.76704   p<0.0001   0.060465   p<0.0001 
p(between 
groups)   0.002112   0.0037   p<0.0001   p<0.0001   p<0.0001 
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Table 3-4: Hausdorff distance measurements from each respiratory phase derived auto-segmentation.  Average values are shown for 
GTV structures, single values shown for IGTV structures.    
Propagation 
Phase 
 Patient A   Patient B   Patient C   Patient D   Patient E  
 
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm) 
0.0  5.99 ± 0.50 7.11  9.07 ± 2.48 10.47  7.52 ± 1.39 15.86  6.42 ± 1.28 4.23  3.68 ± 0.23 6.31 
10.0  6.71 ± 0.60 6.84  9.38 ± 0.84 8.97  7.13 ± 1.50 15.08  5.80 ± 1.46 4.69  6.94 ± 1.87 4.88 
20.0  7.21 ± 2.13 5.81  7.55 ± 1.72 6.60  13.87 ± 0.99 8.43  6.27 ± 1.00 3.52  4.70 ± 1.31 5.02 
30.0  6.03 ± 0.87 6.55  7.32 ± 1.84 7.60  7.58 ± 1.94 11.15  5.63 ± 1.03 4.62  5.16 ± 0.92 4.14 
40.0  9.51 ± 3.09 5.73  8.19 ± 1.56 13.97  13.03 ± 3.00 7.74  6.25 ± 1.00 4.47  6.56 ± 1.01 4.08 
50.0  5.53 ± 0.58 5.26  10.01 ± 2.47 6.52  8.98 ± 1.66 14.52  5.27 ± 0.75 4.23  4.62 ± 1.15 3.58 
60.0  7.38 ± 2.89 7.04  8.72 ± 1.59 9.18  8.16 ± 2.75 7.81  5.95 ± 1.02 5.86  4.81 ± 1.29 3.71 
70.0  7.08 ± 2.14 7.44  8.81 ± 1.98 11.07  6.32 ± 1.56 10.20  5.16 ± 0.77 7.65  4.63 ± 1.64 4.19 
80.0  7.81 ± 1.30 7.44  8.99 ± 2.69 10.26  7.00 ± 1.30 13.98  5.30 ± 1.41 5.18  5.82 ± 0.88 6.58 
90.0  5.83 ± 0.59 6.55  11.54 ± 1.05 7.83  6.40 ± 1.85 11.53  5.21 ± 0.94 4.83  5.91 ± 1.31 4.93 
p(within 
group)   0.0002   0.0008   p<0.0001   0.0883   p<0.0001 
p(between 
groups)   p<0.0001   p<0.0001   p<0.0001   p<0.0001   p<0.0001 
                
Propagation 
Phase 
 Patient F   Patient G   Patient H   Patient I   Patient J  
 
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm)  
GTV ± SD 
(mm) ITV (mm) 
0.0  5.07 ± 0.47 9.56  3.79 ± 0.67 3.52  4.97 ± 0.84 6.36  6.10 ± 1.04 6.26  4.96 ± 1.25 3.71 
10.0  5.55 ± 0.92 5.26  3.30 ± 0.77 4.46  4.61 ± 0.50 5.03  6.08 ± 1.76 7.05  6.47 ± 1.3 5.73 
20.0  6.68 ± 1.11 5.81  3.83 ± 0.39 3.96  4.79 ± 0.56 5.61  5.85 ± 1.23 4.10  5.70 ± 0.76 5.86 
30.0  5.74 ± 1.36 5.30  4.22 ± 1.32 4.07  5.18 ± 0.69 5.40  5.29 ± 1.13 6.94  4.80 ± 0.54 5.26 
40.0  5.67 ± 1.17 6.08  4.07 ± 1.12 4.17  7.32 ± 1.21 5.84  6.94 ± 1.31 5.84  4.88 ± 0.55 6.05 
50.0  6.05 ± 1.40 8.39  3.86 ± 0.75 4.10  4.91 ± 0.77 6.74  5.84 ± 1.52 6.35  5.58 ± 0.85 6.29 
60.0  5.77 ± 1.49 6.68  4.33 ± 1.01 3.27  5.27 ± 0.66 5.51  6.67 ± 1.07 4.01  5.55 ± 0.83 5.73 
70.0  5.59 ± 1.30 6.55  3.48 ± 0.72 4.82  4.93 ± 0.71 5.84  5.40 ± 1.39 6.97  5.06 ± 0.98 6.44 
80.0  5.84 ± 1.15 5.94  4.40 ± 0.73 4.82  5.42 ± 0.50 5.03  5.33 ± 1.09 7.53  5.25 ± 1.14 6.18 
90.0  6.58 ± 1.08 4.88  3.55 ± 0.67 4.74  4.30 ± 0.46 6.36  6.08 ± 1.68 4.72  4.82 ± 1.14 4.08 
p(within 
group)   0.1644   0.0965   p<0.0001   0.1695   0.0095 
p(between 
groups)   p<0.0001   p<0.0001   p<0.0001   p<0.0001   p<0.0001 
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3.4 Discussion and Conclusions 
 In this study, we have included consensus-based, multi-expert GT estimate 
segmentation with a deformable model-based automatic segmentation technique to 
establish a novel framework for anatomical delineation of lung tumours in 4D-CT image 
datasets for radiotherapy.  As 4D-CT becomes increasingly prevalent in the clinic, the 
need for more advanced segmentation strategies increases, as respiratory motion 
influences on thoracic target volumes must be compensated for across larger amounts of 
3D image information. This entails multiple segmentations of the GTV across anywhere 
from 8 to 12 respiratory phase specific CT volumes and generation of the enveloping 
IGTV.  However, while necessary for treatment efficacy, this is an impractical task for 
any clinical workflow.  Image reconstruction techniques such as maximum intensity 
projection (MIP), average intensity projection (AIP), and density override to the tumour 
motion envelope have been implemented to expedite image segmentation for 4D-CT, but 
these methods have shown significant drawbacks in both image segmentation and 
subsequent treatment planning efficacy [31] [32].  The use of MIP images has shown to 
be advantageous in peripheral lung tumours, with limited effectiveness in segmenting 
volumes in the vicinity of the chest wall, mediastinum and diaphragm.  Density override 
also experienced similar drawbacks, where the motion of other structures such as the 
diaphragm can influence the image quality and accuracy of segmentation if in the vicinity 
of the target volume [32].   Use of the AIP image for image segmentation has shown to 
lead to motion blurring with a propensity for increased intra- and inter-observer 
variability [32].  The framework established in this study incorporates the information of 
the entire 4D-CT dataset and largely mitigates inter- and intra-observer variability, one of 
the largest contributors to segmentation related geometric uncertainty currently 
experienced in image-guided radiotherapy, by probabilistically estimating the GT via 
multiple expert segmentations.   
 The diffeomorphic variant of the demons deformable registration technique 
proved capable of providing robust segmentation irrespective of 4D-CT image quality, 
tumour volume geometry, and the choice of respiratory phase CT as the basis for auto-
segmentation.  While different forms of the algorithm exist,the diffeomorphic variant 
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proposed by Vercauteren et al. has previously shown to be effective in thoracic imaging 
with 4D-CT to account for respiratory motion [52] [66] [67] [68].  As Erhardt et al. and 
Beg et al. stated, this is primarily due to the fact that the constraint of transformations to 
diffeomorphisms is natural for medical image registration applications due to the 
preservations of smoothness with respect to anatomical features and its ability to maintain 
connection between connected anatomical structures [52] [69].  Additionally, the speed 
of this method makes it valuable in the context of processing large 4D-CT datasets, as 
shown in previous studies comparing multiple image registration algorithms [70] [71].  
Prior studies have implemented this algorithm in estimation of respiratory lung motion 
with results similar to that of this study.  Work done by Erhardt et al. and Wu et al. 
demonstrated registration errors on the order of millimeters, ranging from ~2 to 8 mm 
and ~1 to 7 mm between respiratory phases, respectively [52] [72].  Both of these studies 
opted to use maximum inhale and maximum exhale phases (0% and 50% phases, 
respectively) as reference phases based on the assumption that these phases show the 
tumour volume at points in time where respiratory motion is at a minimum.  As the auto-
segmented target volumes are created as a result image registration, the registration error 
and symmetric RMS distance measures are comparable in analyzing segmentation in 3D 
image volumes.  Based on that assumption, the results of this study seem to indicate that 
the choice of reference respiratory phase has little effect on the accuracy of auto-
segmentation.  Accuracy is more so dependent on physical characteristics of the tumour 
volume, as complex volumes (i.e. patient 2 and 3) are subject to larger error in 
registration and auto-segmentation due to factors such as size and proximity to the lung 
periphery.  It may also be possible that the STAPLE algorithm's calculation of the 
consensus segmentation itself may depend on the respiratory phase of the 4D-CT dataset, 
and this could be a area of future work.  However, the observations of this study also 
correlate with those made by Erhardt et al. who noted that larger, adherent volumes were 
also subject to increased predicted tumour position error [52].  Wu et al. commented on 
the impact of these errors in the clinical setting when treating lung cancer patients with 
IGRT based on 4D-CT images.  They also noted that the clinical margin to compensate 
for tumour motion in 4D-CT is typically ~5 mm added to the CTV with an additional 7 
mm margin added for the ITV for a total margin size of 12 mm [72].  As distance-based 
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errors were comparable between the two studies, the results of this study seem to support 
the observation made by Wu et al. that dose margins could be reduced in order to 
accommodate more precise treatment of lung tumours using 4D-CT.   
 Image registration and subsequent target volume auto-segmentation based on the 
demons algorithm have previously been shown to be of limited use in the presence of 
contrast enhancement as images of dissimilar intensities and/or variable contrast 
enhancement provide for improper displacement estimates [77].  At the same time, the 
literature on functional and metabolic imaging, contrast enhancement, and/or hybrid 
imaging in segmentation of lung tumours has increased in recent years.  The use of 
contrast and/or additional image modalities to help differentiate tumours from normal 
structures and healthy tissue is well documented in efforts to improve both segmentation 
accuracy and subsequent radiotherapy treatment efficacy [4] [5] [74] [75] [76] [77] [78].  
While the use of such imaging techniques has shown to decrease inter- and intra-observer 
variability while also mitigating potential treatment dosimetry errors, contrast 
enhancement and/or multimodal imaging is not standard for clinical treatment of lung 
cancer and no current clinical guidelines exist concerning the absolute/gradient thresholds 
in manual segmentation.  Additionally, difficulties in defining edges and borders in 
PET/CT image volumes is also an issue in manual segmentation, as observed by 
MacManus et al. [79].  While the Radiation Therapy Oncology Group (RTOG) is 
currently conducting a clinical trial (0515) focused on determining the impact of PET/CT 
fusion in GTV segmentation for NSCLC carcinoma patients, these issues currently 
remain unresolved and lacking in general consensus [80] [81].  Thus, even as functional 
and metabolic imaging becomes more prevalent as an ancillary tool for segmentation of 
lung tumours and target volume definition, the need for segmentation techniques 
operating solely in the context of 4D-CT imaging remains high.    
 Lung tumour segmentation is notably difficult due to the variability in tumour 
geometry from patient to patient [82].  Early-stage patients typically present with small 
masses away from the periphery of the lung subject to less segmentation-related 
uncertainty and allowing for high dose radiotherapy treatment such as SABR and/or 
surgical resection.  Advanced stages typically present as large masses in different 
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locations of the lung, subject to variable amounts of respiratory motion and considerably 
greater geometric uncertainty.  This difficulty largely negates the use of advanced 
segmentation techniques such as atlas-based methods and statistical shape models 
(SSMs) as prior information acquired from different patients does little to inform 
segmentation algorithms on new, incoming cases.  As such, auto-segmentation 
techniques in 4D-CT such as the one implemented in this study typically require 
prerequisite geometrical models such as assisted or manual segmentations of the GTV on 
an individual phase of the 4D-CT dataset.  On top of this requirement is the need for 
multiple expert segmentations when implementing the STAPLE algorithm.  Once this is 
done, processing to auto-segment target volumes and/or assess potential motion of the 
tumour using a number of different algorithms is relatively easy and can be done with 
little to no observer influence, reducing observer variability.  However, this requirement 
still adds significant time and complexity to a clinical workflow such as the one proposed 
in this study.  It also requires multi-physician review, which could create additional 
workflow problems in situations where target definition is time-critical as is typically the 
case for image-guided radiotherapy.  The average manual segmentation time in this study 
was 42.7±18.6 minutes per patient, per physician for an entire 4D-CT dataset.  The 
segmentation strategy proposed in this study would presumably offer considerable 
timesaving and providing for more robust geometrical priors than any individual manual 
segmentation.   
 Clinical use of the methodology proposed in this study would still require 
subsequent physician review and necessary correction of automated segmentations, in 
particular for high risk ROIs, areas of increased uncertainly, and geometrically complex 
tumour volumes that may be subject to irregular respiratory motion.  Nevertheless, 
segmentation workflow from a clinical perspective was shown to be significantly shorter 
than the manual contouring process.  The proposed methodology highlights the strengths 
and possibilities for auto-segmentation strategies in 4D-CT incorporating GT estimate 
algorithms while systematically assessing the accuracy and mitigation of inter- and intra-
observer variability.  Areas for improvement still exist.  The implementation of 
automated or assisted segmentation techniques within individual respiratory phase 
datasets of the 4D-CT may further reduce the time needed to segment the target volume.  
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For example, multi-expert manual segmentation of base/apex slices and subsequent 
propagation may provide increased timesaving and multiple- input segmentation allowing 
for STAPLE segmentation calculation.  Zhang et al. have applied this type of proposed 
methodology previously in kidney segmentation [83].   
 Manual segmentation provides arguably the most accurate basis for any auto-
segmentation method, and the ability to incorporate multiple expert segmentations is 
highly desirable to maximize the utility of available resources within the clinic.  Further 
improvement is still possible, and studies must be performed to assess the accuracy of 
any proposed technique as any time saved in segmenting tumour volumes for IGRT is 
largely negated if accuracy is compromised in doing so.  While some general consensus 
exists on what metrics should be calculated, very little agreement exists on the best way 
to calculate them.  While the CPD algorithm and a surface reconstruction technique based 
on global optimization were utilized in this study, the authors concede that different 
datasets, anatomies, and imaging acquisition techniques may require different 
methodologies and tools for measuring segmentation accuracy and quality.  As such, it is 
important to review the literature to ensure the most effective and accurate methodology 
for future studies.  The development of auto-segmentation techniques in the context of 
contrast enhanced, standalone 4D-CT, and 3D-CT image datasets is of great interest for 
future work in segmentation of not only lung tumours, but also other disease sites and 
different anatomies.  A limitation in this study is the small number of patients and 
observers.  While only ten patients and six observers were utilized from a single 
institution, this provided for approximately six hundred manually defined primary and 
nodal GTV segmentations.  While this yielded a considerable amount of data, it isn't 
enough to support clinical adoption of the technique.  Future work focused on clinical 
implementation of the techniques proposed in this study would require a larger number of 
patients and observers from multiple institutions to ensure a sound clinical workflow is 
developed with any and all forms of variability being accounted for.   
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Chapter 4  
4 Summary, discussion and conclusions 
4.1 Summary 
 The introductory chapter of this thesis presented a general summary of lung 
cancer and the different methods/modalities that exist to treat this deadly disease.  The 
questions that currently exist regarding respiratory motion and its effects on lung tumour 
motion, imaging, and image segmentation in radiation therapy were illuminated and the 
objectives of this thesis were outlined.  The objective of this thesis was to assess the 
variability of lung tumour volume segmentation in the context of 4D-CT imaging for 
image-guided radiotherapy purposes and attempt to mitigate this uncertainty through an 
advanced image segmentation strategy.  The two following chapters addressed these 
objectives, respectively.  The final chapter of this thesis attempts to summarize the main 
findings from this research, followed by a discussion on the clinical relevance of the 
results gleaned from this thesis.  Following a discussion on clinical relevance and impact 
of the work done in chapters 2 and 3, a discussion on possible future investigations is 
presented.   
The work in this thesis addresses scientific questions that have arisen in the 
context of image segmentation, specifically regarding segmentation of tumour volumes 
affected by respiratory motion and how variability within tumour volume segmentation 
plays a role in image-guided radiotherapy.  While 3D-CT imaging in image-guided 
radiotherapy has and continues to be prevalent, 4D-CT imaging as a basis for 
radiotherapy is still relatively new and was implemented in the clinical setting relatively 
quickly.  As such, to understand and fully utilize the potential for 4D-CT imaging, it must 
be subject to key research questions that address any and all forms of uncertainty that 
exist within the method. 
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4.2 Impact of target volume segmentation accuracy and 
variability on treatment planning for 4D-CT based non-
small cell lung cancer radiotherapy 
 The first study of this thesis, presented in chapter 2, investigated the effects of 
variable target volume segmentation on subsequent radiotherapy treatment planning in 
the setting of reference standard target volume segmentation.  Multiple radiation 
oncologists with extensive experience in treating lung cancer patients participated in this 
study to provide high integrity, clinically acceptable target volume segmentations for 
analysis.  Additionally, a reference-standard, or 'gold-standard" segmentation was made 
available by way of the STAPLE algorithm [1] to provide for a baseline segmentation 
against which all expert segmentations could be compared at pre- and post-treatment 
planning stages of image-guided radiotherapy.  This is important because it allows for the 
analysis of both segmentation variability as well as the subsequent dosimetric variability 
after treatment plan optimization.  It is important to analyze dosimetric variability in the 
context of both physical and biological dose characteristics.  This can be done through 
the various metrics used in chapter 2 as well as many others that appear in the literature, 
all of which are tailored to specific endpoints and/or different aspects of radiotherapy 
treatment planning analysis.  Even with expert participants in this study, a great deal of 
variability was observed in target volume segmentation at pre-treatment planning stages.  
This variability extended into the treatment planning setting leading to largely non-
uniform dose distributions and clinically unacceptable treatment plans relative to the 
STAPLE-derived ground truth (GT) estimate.  Additionally, effects on tumour control 
probability (TCP) included reduced overall observer TCPs with large variances as well as 
variable normal tissue complication probabilities (NTCP) for healthy lung.  The effects 
varied on a relatively patient-specific basis where complex tumour geometries and 
baseline manual segmentation difficulty as gauged by observers typically correlated with 
increased segmentation and dosimetric variability.  From this work we concluded that 
more advanced segmentation strategies need to be adopted in conjunction with 4D-CT 
imaging to fully address the issue of geometric uncertainties related to respiratory motion 
effects in target volume segmentation of lung tumours in radiotherapy.   
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4.3 Consensus-based lung tumour volume auto-
segmentation in four-dimensional computed 
tomography 
 In chapter 3, it was shown that a great deal of variability exists within target 
volume segmentation of lung tumours in 4D-CT based radiotherapy.  This uncertainty 
extends into the treatment planning setting, and as such, segmentation strategies must be 
devised to address this uncertainty and provide for more consistent and accurate 
radiotherapy planning.  In light of this observation, a novel auto-segmentation strategy 
employing the STAPLE algorithm and a diffeomorphic demons' registration model was 
employed to provide for multi-expert GTV and IGTV segmentations of lung tumours 
from 4D-CT datasets.  Six physicians manually segmented 4D-CT datasets of Ten 
NSCLC lung cancer patients.  Based on these segmentations, ground truth estimates were 
constructed using the Simultaneous Truth and Performance Level Estimation (STAPLE) 
algorithm for the gross tumour volume (GTV) on each individual phase of the 4D-CT 
data set and the internal gross target volume (IGTV.  STAPLE GTVs on each individual 
phase of the 4D-CT dataset were auto-segmented to all other phases providing auto-
segmented GTVs and IGTVs based on ground truth estimate segmentations (STAPLE) 
from each individual respiratory phase of the 4D-CT dataset for all ten patients.  
Accuracy assessment of auto-segmentation employed graph cuts for 3D-shape 
reconstruction based on methods proposed by Lempitsky and Boykov [2] [3] and point-
set registration-based metrics employing the coherent point drift (CPD) algorithm [4].  In 
this study, we proposed an alternative segmentation strategy for 4D-CT data sets 
developed in conjunction with GT estimation and robust surface fitting algorithms for 
improved segmentation visualization and analysis.  The accuracy of auto-segmentation 
was shown to be largely independent of selection of the initial propagation phase.  
Rather, the construction of the IGTV based on auto-segmented GTVs within the 4D-CT 
dataset provided more accurate and reliable target volumes with respect to manual-
segmentation based ground truth estimates.  The results of this study could provide a 
basis for implementing auto-segmentation of consensus volumes in 4D-CT data-sets 
clinically and reduce the clinical workload of manual segmentation for physicians while 
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mitigating geometric uncertainties that result directly and/or indirectly from image 
segmentation. 
 In addition to the consensus segmentation strategy used in this study, many 
alternative strategies for multi-label fusion exist including STAPLE-variants, majority-
voting, non-local mean based label propagations and those presented by Biancardi and 
Jirapatnakul [5].  Additionally, a multitude of alternative segmentation strategies have 
been proposed previously.  While a general framework and validation has been proposed 
in chapter 3 for propagation of multi-label fusion segmentations, there is an exceptional 
amount of future work that could be done to explore how best to utilize these tools and 
techniques for improved image segmentation outside of the context of either lung tumour 
volume definition and/or image-guided radiotherapy.    
 
4.4 Clinical Significance 
4.4.1 Clinical impact of target volume segmentation accuracy and 
variability on treatment planning for 4D-CT-based non-small 
cell lung cancer radiotherapy 
 The study presented in chapter 2 on target volume segmentation variability 
indicates that there is still a clinical problem surrounding the identification of treatment 
planning target volumes in 4D-CT based lung cancer radiotherapy.  While 4D-CT does 
improve the image quality of thoracic CT datasets, target volume definition for 
radiotherapy purposes is still subject to variability amongst experts.  This variability 
subsequently plays a role in the treatment planning process.  Lung cancer was chosen as 
the disease of interest for this study because of the role of respiratory motion in 
conjunction with the highly variable geometry inherent to lung tumours.  Both 
respiratory-gated and non-gated scenarios were assessed to ensure robust analysis on two 
clinically relevant treatment strategies.  Both scenarios were subject to comparable 
degrees of variability, suggesting that segmentation-related geometric uncertainty is large 
enough to confound any possible distinctions that could be made regarding the 
differences between gated and non-gated treatment strategies.  The degree of uncertainty 
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observed in chapter 2 leads one to believe that treatment techniques involving larger 
degrees of beam modulation and/or dose escalation may put the patients at increased risk 
and at the very least, lower the perceived treatment efficacy.  To mitigate this problem, 
two possible clinical solutions exist.  The first involves developing an image 
segmentation strategy that incorporates multiple expert segmentations while also 
eliminating inter-/intra-observer variance in conjunction with 4D-CT to mitigate any 
image related uncertainty as a result of respiratory motion.  The second strategy to 
mitigate this uncertainty would involve undertaking a large scale, multi-center study to 
develop guidelines and treatment margin recommendations.  Recommendation would be 
made analogous to those made to compensate for factors such as microscopic disease and 
treatment setup error that have previously been adopted in CTV and PTV margin 
construction.  Finally, the inclusion of functional imaging could also help to address this 
issue.  PET-CT imaging is becoming more common for lung cancer patients in both the 
diagnostic and treatment settings.  Previous studies have shown that it provides for more 
precise image segmentation and as such, it's inclusion into widespread clinical practice 
for 4D-CT based lung cancer radiotherapy would be extremely valuable [6] [7] [8] [9].     
4.4.2 Clinical feasibility of consensus-based lung tumour volume 
auto-segmentation in four-dimensional computed 
tomography 
 Of the two strategies proposed in chapter 2 and section 4.4.1 for dealing with 
segmentation-related geometric uncertainties, one was chosen for analysis in chapter 3.  
This strategy involved developing an image segmentation strategy that incorporates 
multi-expert label fusion via the STAPLE algorithm for multi-expert consensus 
segmentations eliminating inter-/intra-observer variance in conjunction with 4D-CT to 
mitigate any image related uncertainty as a result of respiratory motion.  While chapter 3 
focuses on the suggested framework and accuracy of such a method, the clinical 
feasibility of this technique is still somewhat unknown.  While other anatomical sites 
could implement anatomical atlases in conjunction with the STAPLE algorithm to 
facilitate consensus-based segmentation, lung tumours and/or pulmonary nodules present 
a challenging problem due to their variability in shape and anatomic connection to 
neighboring pulmonary structures from patient to patient.  This renders anatomical atlases 
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to be of limited use.  For such a methodology to be adopted in the context of lung cancer, 
some form of manual segmentation is almost always required for subsequent 
implementation of label fusion.  As such, consensus-based segmentation in the context of 
lung cancer requires multiple physicians segmenting tumour volumes for a single patient 
in the clinic.  This presents an obstacle for consensus-based segmentation, as current 
clinical practice doesn't facilitate multiple physician participation in single-patient target 
volume definition.  Noticeable decreases in segmentation time in conjunction with 
improved accuracy would need to be demonstrated to trigger any motivation for 
implementing the practice proposed in chapter 3.  However, with the growing amount of 
literature on both multi-label fusion techniques [10][11][12][13][14] and auto-
segmentation algorithms in the context of multiple imaging modalities [15] [16] [17], it 
should behoove larger cancer centers with extensive research programs to adopt more 
advanced image segmentation strategies for IGRT to both improve segmentation and 
subsequent treatment quality and efficiency. 
4.4.3 Limitations 
 As both studies that comprise this thesis utilized the same patient group and 
segmentation data, a shared limitation of both works is the small number of patients and 
physician observers. However, despite the small number of patients and observers, the 
volume of data gathered for analysis was quite large due to the nature of 4D-CT imaging.  
More comprehensive studies of a similar nature to those presented in chapters 2 and 3 
involving increased numbers of patients and physician observers would require a larger-
scale effort.  Multi-institution, multi-observer studies would address this issue, however, 
the logistics of such an undertaking are quite complicated and the duration of such a 
study would be greatly extended.  Also, as pointed out in chapter 2, considerable 
variability exists in 4D-CT image segmentation amongst the small group of experts.  
Therefore, it is logical to assume that larger patient and observer groups are required only 
when further progress can be made to address the uncertainty within a single-institution 
thoracic working group such as the one employed in the studies of this thesis.    
 Standard radiotherapy treatment schemes (60Gy/30rx) were only considered for 
the work in chapter 2.  This poses as a limitation given the current trends of increased 
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beam modulation and dose escalation in lung cancer radiotherapy.  Treatment techniques 
implementing emerging technologies such as the TrueBeamTM system and/or dose oligo-
fractionation such as stereotactic ablative radiotherapy (SABR) are becoming more 
common for lung cancer radiotherapy.  As such, the work in this thesis should be 
extended beyond the simple standard step and shoot, 2Gy per fraction IMRT technique.  
In doing this, a more comprehensive understanding of target volume uncertainty and 
auto-segmentation capability can be acquired and implemented in a clinical setting to 
further enhance 4D-CT based radiotherapy.  
 The STAPLE algorithm has emerged over the past few years as the gold standard 
for multi-label fusion and consensus segmentation for GT estimates.  However, as this 
happens, advancements are made further developing STAPLE and its variant algorithms 
to develop more robust and reliable GT estimates.  As such, it remains a possibility that 
these techniques could be integrated into an image segmentation workflow analogous to 
the study in chapter 3 and provide for superior results.  Additionally, the presence of 
functional and/or morphological information by way of contrast enhanced CT, PET-CT, 
MRI, and/or other image modalities could further enhance the accuracy of segmentation, 
manual and/or automated.   
 
4.5 Future work 
 The variability assessed in chapter 2 was done so in the context of relatively low 
prescription and fractionation dose.  As lung cancer radiotherapy moves into dose 
escalation techniques such as stereotactic body radiotherapy (SBRT) and/or stereotactic 
ablative radiotherapy, future work focused on applying these more aggressive treatment 
planning techniques in a way similar to the methodology proposed in chapter 2 would be 
of value to assess whether or not the observed variability would potentially be mitigated 
or exacerbated.  This may also involve further sub-specification of the patients group 
and/or the observer group to make sure the target segmentation variability could be 
explicitly attributed to factors such as disease staging, tumour location and size, and 
observer expertise.  Additionally, through implementation of IMRT, supplementary 
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uncertainties arise in relation to treatments implementing three-dimensional conformal 
radiation therapy (3DCRT) such as the interplay effect between anatomical motion due to 
respiration and the multi-leaf collimator (MLC) used for treatment beam shaping.  More 
explicitly, this interplay effect refers to the interplay of concurrent motion of anatomy 
and MLC, and can cause discrepancies between calculated and delivered doses to the 
target volume during radiotherapy treatment can arise and produces extraneous variability 
in the context of segmentation accuracy studies.  Thus, studies such as the one presented 
in chapter 2 would benefit from additional analysis of this interplay effect in the context 
of variable target segmentation to explicitly classify and categorize treatment related 
uncertainties in IGRT.  
 The STAPLE algorithm was adopted for use in chapters 2 and 3 without an 
explicit validation study.  Prior applications of the STAPLE algorithm have shown it to 
be both robust and accurate across a variety of modalities and implementations.  With 
that being said, future work on the validation of the STAPLE algorithm in the context of 
4D-CT imaging utilizing simulated respiratory motion (both regular and irregular 
breathing patterns) alone would be of value to eliminate any possible extraneous variation 
due to the algorithm itself and optimize it use in the context of image-guided 
radiotherapy.   
 The integration of a more complex image segmentation workflow, such as that 
proposed in chapter 3, into routine clinical use would be quite difficult.  Larger-scale 
validation studies would be required and guidelines for multi-physician tumour volume 
segmentation for single patients would need to be established.  This type of ancillary 
work makes reform to the current clinical model of tumour and subsequent target volume 
definition somewhat unappealing from a logistics perspective.  However, the method 
proposed in this thesis would be no different than any other advanced segmentation 
strategy employed to a similar end.  As the literature on this subject continues to increase, 
clinical implementation of proposed techniques remains rare.  Therefore, it is important 
for clinicians and researchers alike to understand the large-scale effort needed to adopt 
improved image segmentation strategies for clinical use.  Pilot studies and clinical cases 
would provide a starting point in adopting improved segmentation techniques, and from 
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there decisions can be made on their clinical viability and the potential for improved 
radiotherapy treatment planning.     
 The idea of integrating advanced image segmentation techniques into clinical 
workflows may not be feasible and/or appealing to clinicians for a number of reasons.  
Regardless of those reasons, there is another option for mitigating target volume 
uncertainty in the context of image-guided radiotherapy for lung tumours and other 
anatomies with or without 4D-CT imaging.  Previous RTOG protocols and ICRU reports 
have put forth margin recommendations for lung tumour target volumes for a myriad of 
different image acquisition modalities and radiotherapy treatment schemas.  A similar 
undertaking focused on treatment target volume margin recommendations to account for 
tumour volume segmentation variability would provide an alternative method to 
advanced segmentation strategies.  A study of this nature would require the participation 
of multiple centres, multiple physicians, and would need to be catered to each disease site 
specifically as margin recommendation may differ depending on the anatomy of interest. 
 While chapter 3 focused on implementing a novel automatic segmentation 
strategy for lung tumour volume definition in 4D-CT images, other studies have also 
addressed the topic, each with its own intricacies and methodology.  To date, very little 
literature on this topic includes analysis of downstream treatment planning based on auto-
segmented target volumes.  This type of analysis is paramount when image segmentation 
is performed in the context of image-guided radiotherapy.  No novel target volume 
segmentation technique can ever be considered for clinical use without some form of 
verification and/or validation at the radiotherapy planning stages.  Subsequent dosimetric 
analysis, similar to that presented in chapter 2 would provide a clearer picture on the 
integrity of a novel segmentation strategy and allow for a more informed discussion on 
how auto-segmentation of radiotherapy target volumes plays a role in treatment efficacy 
and outcomes.    
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4.6 Conclusions 
The most significant finding of the thesis are summarized below: 
1) A considerable amount of variability currently exists in target volume 
segmentation for lung tumours in the context of 4D-CT imaging.  Based on 
primary and nodal lung tumour target segmentations amongst multiple experts in 
the presence of a reference standard, this variability extends into the treatment 
planning stages for IMRT in both respiratory-gated and non-gated scenarios. 
2) Although the use of 4D-CT allows for more accurate target volume segmentation 
by accounting for respiratory motion, further improvements need to be made to 
provide for more consistent target volume segmentation.   
3) To address the problems stated above, an alternative segmentation strategy for 
4D-CT data sets has been developed in conjunction with ground truth estimation 
and robust surface fitting algorithms.  This provides a mechanism for improved 
target volume segmentation and incorporates tools for in-depth analysis to 
validate the proposed strategy.   
4) The proposed strategy incorporates the information of the entire 4D-CT dataset 
and largely mitigates inter- and intra-observer variability by probabilistically 
estimating the ground truth via multiple expert segmentations. The accuracy of 
auto-segmentation was shown to be largely independent of selection of respiratory 
phase propagation.  Additionally, construction of the IGTV based on auto-
segmented GTVs within the 4D-CT dataset provided more accurate and reliable 
target volumes with respect to manual-segmentation based ground truth estimates.  
 
 The work in this thesis assesses the uncertainty related to 4D-CT image 
segmentation that currently exists in the clinical context for treatment of lung cancer 
patients.  The benefit of this work is that it provides for quantitative analysis regarding 
this uncertainty to potentially inform and improve future lung cancer treatment using 
image-guided radiotherapy.  This project also lays the foundation for future work focused 
on techniques for mitigating segmentation-related geometric uncertainty.  The uncertainty 
that exists can be addressed through a number of different strategies and techniques.  
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Regardless of the measures taken to address this uncertainty, lung cancer patients can be 
treated more aggressively with radical intent using radiation therapy and achieve 
improved local control.  In addition to quantitatively assessing this uncertainty, we have 
also proposed an improved image-segmentation strategy to mitigate the observed target 
volume definition variability.  It is this author's hope that these works are built upon and 
further improved not only in the context of 4D-CT based lung cancer radiotherapy, but 
also other disease sites and imaging modalities.  At the same time, it is important to find 
ways to integrate the work of this thesis and similar strategies into the current clinical 
workflow such that continual improvements made can and will positively influence 
current and future standards of care for lung cancer patients. 
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Appendix A: The STAPLE Algorithm 
The STAPLE algorithm concurrently computes a probabilistic estimate of the 
ground truth segmentation and the observer's segmentation performance level.  As per 
Warfield et al. [1], this is done by implementation of the expectation-maximization 
algorithm [2].  Segmentation quality amongst observers, or performance level is 
measured by sensitivity and specificity parameters.  Sensitivity and specificity of an 
observer's segmentation j is given by pj and qj, where pj represents the "true positive 
fraction" (sensitivity), given by:  
  $  1  1 (2) 
And qj represents "true negative fraction" (specificity), given by: 
  $  0  0 (3) 
Where Dij is the decision made by the observer in segmentation j for voxel i (1 = present 
in observer segmentation, 0 = absent in segmentation) and Ti is the true segmentation for 
voxel i.  The STAPLE algorithm can be initialized in two different ways.  The first 
assumes sensitivity and specificity for each observer, or by assuming an initial GT 
segmentation. The first assumption is typically the most advisable as all observers are 
assumed to have the same sensitivity and specificity and the initial estimate GT is simply 
the weighted average of segmentations.  The EM algorithm subsequently estimates the 
performance level parameters (p, q) in an iterative fashion while maximizing the log 
likelihood function given by:  
̂, "  arg max, ln u$, |, " (4) 
The E-step of the EM algorithm aims to compute the unobserved true segmentation.  This 
is done by estimating the conditional expectation of the complete data log likelihood 
function.  To do this, a conditional probability density function (PDF) of the true 
segmentation given the observer segmentation and initial estimates of pj and qj is derived 
such that for each voxel i the true segmentation is calculated by the following:  
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u$, !", !"  ∏ u 	$, !", !"
 u"∑ ∏ u 	$, !", !"
 u"′  (5) 
  Where f(Ti) is the prior probability of Ti and k is the iteration step.  As the true 
segmentation is a binary random variable, the conditional probability that the voxel lies 
outside the true segmentation f(Ti=0) is simply 1-f(Ti=1).  The estimate of probability 
that the true segmentation is Ti=1 is then stored for each voxel.  In the case of a binary 
segmentation, we consider Ti=0 and Ti=1 and factor across all experts for sensitivity and 
specificity parameters to derive the following: 
!"  u  1"  u 	$  1, !", !"
  u  1"  !":  	1 - 
!"
:P  (1) 
 
!"  u  0"  u 	$  0, !", !"
  u  0"  !":  	1 - 
!"
:P  (1) 
Where j: Dij = 1 denotes the set of indices for which the decision of observer j at voxel i 
(Dij) equals 1.  This formulation allows one to derive an single expression for the 
conditional probability of the true segmentation for each voxel, referred to as weight 
variable, Wi(k-1). 
!"  u  1$, !", !"   !"!" & !" (6) 
The M-step estimates the performance parameters by way of the maximization step of the 
EM instance.  Given the estimated weight variables solving for conditional probabilities 
of true segmentation, the values of observer performance level parameters maximizing 
the conditional expectation of the complete data log likelihood function can be found.  
These performance level parameters are estimated using the following equations:   
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!"  ∑ !":∑ !"  (7) 
 
!"  ∑ 	1 - !"
:P∑ 	1 - !"
  (8) 
The sensitivity estimator given by pj is interpreted as the ratio of the jth observer true 
positive detections to the total amount of segmentation Ti=1, where the voxel is weighted 
by the segmentations satisfying Ti = 1.  The specificity estimator, qj, is interpreted as an 
estimator of specificity given an observer's segmentation satisfying Ti=0.  The resulting 
segmentation can be regarded as multi-expert ground truth estimate, calculated in a more 
robust manner than typical P-map based GT estimate segmentation. 
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